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The study of platelet messenger and micro-RNAs is of increasing interest 
owing to the fact that platelets contain the machinery to splice and 
translate mRNA into proteins in response to inhibitory or activating 
signals. However, the relatively small size (roughly 4000-5000 transcripts) 
and short half-life of the platelet transcriptome makes this a technically 
challenging aspect of platelet biology to investigate.  
 
The aims of these thesis investigations were therefore to optimise 
protocols for the isolation of platelets for downstream RNA analyses and 
function testing, to investigate the functional capabilities of platelet 
subpopulations rich in RNA, and to understand the functional and 
transcriptomic impact of gene mutations predicted to influence platelet 
function.   
 
I found that the optimal method for isolating platelets from whole blood is 
to use simple single step centrifugation to obtain platelet rich plasma. 
This method is as effective as more involved methods at reducing white 
blood cell contamination whilst causing minimal platelet activation. Using 
this method in combination with flow cytometric cell sorting techniques I 
was able to isolate the newly formed reticulated platelet sub-population 
and to confirm the link between reticulation status and increased RNA 
content. Furthermore, using a range of platelet function assays I 
demonstrated that reticulated platelets are more reactive than 
non-reticulated platelets. By obtaining blood samples from a patient with 
a PLA2G4A mutation I was able to show that loss of cPLA2α enzymatic 
activity alters both platelet function and the expression of certain mRNA 
transcripts. My investigations using samples from a range of patients with 
bleeding tendencies show the benefit of combining deep platelet 
phenotyping with next generation sequencing to understand the 
causation of bleeding disorders.  
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Together these investigations highlight the utility of genomic DNA and 
platelet specific mRNA studies in providing novel insights in to pathways 
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1.1 The cardiovascular system and haemostasis 
 
The cardiovascular system consists of the heart, a muscular pump, and a 
closed system of vessels that include arteries, veins and capillaries. 
During mammalian development the cardiovascular system is the first 
organ system to reach a functional state with a heartbeat detectable four 
weeks after fertilisation 1. In the adult human, the principle function of the 
cardiovascular system is to transport substrates required for biochemical 
processes and to remove their potentially harmful waste products 2. The 
complex integrated control mechanisms of the cardiovascular system 
ensure that adequate blood supply is maintained irrespective of 
differences in physiological demand.  
 
Central to the maintenance of the cardiovascular system is the process of 
haemostasis. This series of integrated biochemical and cellular events 
can be grouped into the three stages of vascular spasm, platelet plug 
formation (primary haemostasis) and coagulation (secondary 
haemostasis) 3. Together these stages function to maintain the balance 
between blood in its resting liquid state and blood in its gel-like solid state 
required for the formation of blood clots in response to vessel wall injury 
4. Deviations in this balance can lead to haemorrhage or thrombosis.  
 
Cardiovascular disease (CVD) encompasses all diseases affecting the 
heart or circulatory system and is the leading cause of death worldwide 
5,6. In the United Kingdom alone CVD affects over 7 million people costing 
the National Health Service in excess of £11 billion each year 7. 
Consequently, research to better understand the pathophysiology of such 
diseases in order to design novel therapeutic strategies is a major focus 
within the life science community. 
 24 
1.2 The platelet  
 
Central to the process of haemostasis and to the development of many 
cardiovascular pathologies are platelets.  
 
After the advent of the achromatic lens microscope in 1826, physicians 
Albert Donne, George Gulliver, William Addison and Max Schultze 8 
independently produced the earliest recorded observations of platelets in 
whole blood describing them using terms such as ‘globular masses’, 
‘colourless corpuscles’ or ‘spherules’. It wasn’t until 1874 that William 
Osler 9 published work clearly recognising platelets as independent 
cellular bodies 10; this pivotal discovery provided the foundations for the 
work of Giulio Bizzozero who was the first investigator to assign function 
to the platelet 11,12. In 1882, in a series of in vitro and in vivo experiments 
Bizzozero documented the role of platelets in coagulation; specifically 
noting their adherence to vessel walls and interactions with fibrin. 
Collectively these investigators provided the scientific community with the 
fundamentals of platelet biology 13.     
 
 
1.2.1 Platelet production and clearance  
 
Twelve years prior to his publications regarding platelets Bizzozero had 
been the first to discover megakaryocytes but had failed to recognise 
them as the platelet’s cell of origin. It took until 1906 for James Homer 
Wright to use his newly developed Wright’s stain to characterise the 
relationship between megakaryocytes and platelets by visualising their 
granules and thus seeing the similarities in their size and shape 14.  
 
Megakaryocytes are highly specialised, large myeloid cells found mainly 
in the bone marrow and are the parent cell to platelets. During maturation 
megakaryocytes begin to increase in volume and fill their cytoplasm with 
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membrane systems, organelles, granules, proteins and mitochondria 
essential to the process of platelet production 15.  
 
Many modes of platelet production from megakaryocytes have been 
proposed but it is the pro-platelet theory that is the most well established 
and rigorously supported by both in vitro and in vivo experiments 16,17. In 
this model mature megakaryocytes produce pseudopods that traffic the 
proteins and organelles from the megakaryocyte, through the microtubule 
systems and into structures known as pro-platelets. Pro-platelets are long 
cytoplasmic extensions of the megakaryocyte cell body; these branched 
structures can be seen microscopically to extend into the sinusoidal blood 
vessels of the bone marrow and to contain multiple platelet-sized 
swellings that become the site for platelet release 18,19. The ends of 
pro-platelets repeatedly bend and branch, thus greatly amplifying the 
surface upon which platelets can be produced 20. Eventually pro-platelets 
are released as individual platelets through the narrowing of the 
pro-platelet extensions and exposure to shear forces in the bloodstream 







Figure 1.1 Pro-platelet model of platelet formation 
Before platelets are released, microtubules firstly disassemble and move 
towards the plasma membrane and eventually fill the pseudopodia 
pushed out by the megakaryocyte. Organelles and granules are trafficked 
into the extending pseudopodia and branching occurs to increase the 
amount of pro-platelet containing ends. Eventually, pro-platelets, 
organelles and granules become trapped in close proximity and are 
released from the main megakaryocyte body. Subsequent microtubule 






A normal human platelet count falls within the range of 
150-400x109 cells/L in the circulating blood and is kept constant by 
maintaining the balance between production and clearance 21. Platelets in 
the circulation have a lifespan of 8-11 days; consequentially each day 
roughly 10% of the total platelet population is renewed. As with the 
theories of production, there are also multiple hypotheses offered for the 
control of platelet lifespan and senescence. In more recent investigations 
the role of the intrinsic apoptosis pathway in the regulation of platelet 
lifespan has gained more acceptance. Platelets have been shown to 
express a number of pro-apoptotic proteins including Bak and Bax and 
pro-survival proteins including Bcl-2, Bcl-xL and Mcl-1 22. A shift in the 
balance towards the pro-apoptotic group will allow Bak and Bax to cause 
enough mitochondrial damage to trigger caspase activation and initiation 
of apoptosis 23. In disease states such as immune thrombocytopenic 
purpura, characterized by excessive platelet destruction, an 
antibody-mediated method of platelet clearance is favored. In such cases 
IgG autoantibodies bind to the platelet surface resulting in opsonisation 
and subsequent Fc receptor-mediated phagocytosis by macrophages in 
the spleen 24.   
 
 
1.2.2 Platelet structure  
 
Platelets are small, anuclear cell fragments measuring on average 
2-5 µm with a mean cell volume of 6-10 fL. The outer platelet plasma 
membrane is a standard phospholipid bilayer and is the site for surface 
receptor expression. These surface receptors are numerous and play an 
essential role in determining platelet reactivity and responsiveness to 
external signals. Connected to the plasma membrane is the open 
canalicular system (OCS) of channels extending deep into the cytoplasm 
and functioning to transport substances into the platelet cytoplasm and 
out of the secretory granules 25. There are two types of secretory 
granules within the platelet cytoplasm, α and dense, which release their 
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contents to mediate a variety of platelet functions in response to platelet 
activation. Granule content is outlined in Tables 1.1 and 1.2. In addition to 
the OCS there is also a dense tubular system (DTS) of channels derived 
from the smooth endoplasmic reticulum of the parent megakaryocyte that 
primarily functions to facilitate movement of calcium and enzymes 
needed to support activation 26.  
 
Platelets also have a highly specialised cytoskeleton which rapidly 
reorganises itself upon platelet activation to facilitate shape change from 
a smooth discoid cell to a structure of irregular pseudopodia projections 
27. The resulting increase in platelet surface area facilitates additional 





Table 1.1 Major components found within α-granules 






Table 1.2 Major components found within dense granules 
Table adapted from Platelets 3rd edition, 28 
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1.3 Platelet activation, adhesion and aggregation  
 
The primary role of platelets is to limit blood loss after vessel injury 
through the formation of a thrombus. In order for platelets to stick to the 
site of injury they must first come into very close contact with the vessel 
wall and remain there until platelet-endothelium interactions are 
permitted. Due to the relative size of platelets and red blood cells 
(RBC’s), under normal blood flow platelets are influenced by the motion 
of RBC’s and are pushed towards the vessel wall (Figure 1.2 A). Under 
these conditions platelets can begin to slowly roll over the surface of the 
endothelium lining the vessel and interact with endothelial cells through 
weak interactions between von Willebrand Factor (vWF) and glycoprotein 
1bα on the platelet surface 29.  
 
If the vessel wall is damaged significantly, as in the case of 
atherosclerotic plaque rupture, sub-endothelial matrix proteins such as 
collagen become exposed 30. Platelets readily adhere to collagen through 
the glycoprotein receptors Ia-IIa (integrin α2β1) and VI 31. Signalling 
through glycoprotein VI results in an increase in intracellular calcium 32 
leading to platelet activation, shape change and the release of mediators 
such as thromboxane A2 and adenosine diphosphate (ADP) which act 
through the prostanoid (TP) or P2Y12 and P2Y1 receptors respectively, to 
further recruit other platelets into the forming platelet plug. These 
platelet-platelet interactions, known as platelet aggregates, are largely 
mediated through the glycoprotein IIb-IIIa receptor that binds vWF and 
fibrinogen attracting yet more platelets to the site of plug formation 33 
(Figure 1.2 B). A summary of these events can be found in Figure 1.2.  
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Figure 1.2 A schematic representation of platelet interactions with 
the vessel wall following injury 
The velocity of flowing blood in relation to the stationary vessel wall 
results shear forces that will allow larger blood cells to move through the 
centre of the centre of the flow. This in turn will force platelets that are 
smaller and less dense to the edge of the flow close to the vessel wall 
(A). In high shear conditions initial tethering of platelets to collagen occurs 
through the GP 1b-V-IV mediated by vWF. Stronger adhesion is achieved 
through collagen binding to GPVI and integrin α2bβ3. This results in 
platelet activation, shape change and granule release. Fibrinogen 
mediated platelet aggregation occurs though binding to activated α2bβ3 
and the growing thrombus is stabilised through strong interactions 
between collagen and vWF with the activated α2bβ3 and α2β1 integrins (B).  
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1.4 Platelet activators and inhibitors  
 
In addition to collagen, platelets can respond to a wide range of other 
endogenously produced activating and inhibitory mediators, which act 
upon their large repertoire of cell surface receptors, to facilitate various 
physiological functions. These mediators, and their synthetically produced 
equivalents, can be taken advantage of experimentally to assess platelet 
reactivity and are utilised in many standard platelet function assays. A 
summary of the activators and inhibitors used in this thesis can be found 
in Figure 1.3. 
 
This section will discuss those most relevant to this investigation, all of 
which signal through G-protein coupled receptors (GPCRs). GPCRs are 
formed from a single polypeptide chain with seven transmembrane 
domains and interact with G-proteins within the plasma membrane. 
These G-proteins, formed from an alpha, a beta and a gamma subunit, 
bind guanosine triphosphate when active (GTP) or guanosine 
disphosphate when inactive (GDP). When a signalling molecule binds to 
the GPCRs active site a conformational change occurs allowing GTP to 
replace GDP on the alpha subunit. The receptor is not active until the 
alpha subunit bound to GTP dissociates from the beta-gamma dimer to 
interact with other membrane proteins, enzymes, second messengers or 




Thrombin, formed through conversion of prothrombin by the actions of the 
prothrombinase (complex consisting of Factors Xa and Va), is an enzyme 
with an essential role in haemostasis. With specific reference to platelets, 
thrombin acts upon the protease-activated receptors 1 and 4 (PAR-1 and 
PAR-4). PAR receptors are a type of GPCR that first requires the 
cleavage of a tethered peptide ligand that can go on to bind to the 
receptor to activate signalling 37. Synthetically produced thrombin related 
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activating peptide-6 (TRAP-6) mimics the portion of the PAR1 receptor 
revealed by thrombin cleavage and so acts as a PAR1 agonist. PAR 
receptors signal through Gq proteins to stimulate phospholipase C (PLC) 
and inositol triphosphate (IP3) to increase intracellular calcium levels. The 
receptors also signal through Gi proteins to alter PI3K/Akt pathways and 
through G12/13 proteins to alter rho kinase signalling pathways to 




Stored within platelet dense granules ADP is actively released from the 
platelet secondary to platelet plug formation initiated by collagen and 
thrombin signalling. ADP functions as a platelet agonist by binding to the 
P2Y1 and P2Y12 receptors. P2Y1 activates PLC and IP3 via the Gq protein 
to increase calcium ion concentrations that initiate platelet aggregation 
and shape alteration whereas P2Y12 inhibits adenylyl cyclase to 
consequently decrease intracellular cAMP levels via the Gi protein 
leading to an enhanced stability of the aggregate and further granule 
content secretion 39,40. In addition P2Y1 and P2Y12 receptors work in 
concert with the glycoprotein IIb/IIIa (integrin α2bβ3) fibrinogen receptor 
to activate phospholipase A2 (PLA2) which catalyses the liberation of 
arachidonic acid from membrane phospholipids; a crucial step in the 




Platelet activation in response to epinephrine is mediated through the 
activity of α2-adrenergic receptors coupled to Gi proteins that inhibit cAMP 
formation by suppressing adenylyl cyclase activity. Reducing cAMP 
formation effectively alleviates a block on platelet signaling that is 
ordinarily in place to prevent inappropriate platelet activity 42.    
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1.4.4 Arachidonic acid and Thromboxane A2  
 
Through the activity of cyclooxygenase (COX), arachidonic acid (AA) is 
converted to prostaglandin H2 that is further converted to thromboxane A2 
(TxA2) by thromboxane synthase 43. TxA2 binds to the 
thromboxane-prostanoid (TP) receptor and signals through the Gq and Gi 
proteins. Activation of this receptor leads to phosphorylation of myosin 
light chain kinase through the activity of PLC as well as an increase in 
intracellular calcium through the activity of IP3 44. U46619 is a synthetic 
TP receptor agonist and is used experimentally to give further information 
in addition to results obtained using AA 45. It enables investigators to 
discriminate between effects due to inhibition of endogenous TxA2, as in 
the case of aspirin, or due to changes in TP receptor function; aspirin will 
block responses to AA but not those to U46619. 
 
1.4.5 Prostacyclin (PGI2) 
 
Also produced from AA metabolism through the actions of COX and 
prostacyclin synthase enzymes, PGI2 is a platelet inhibitor 46. PGI2 exerts 
its inhibitory effects through the platelet prostacyclin receptor (IP) coupled 
to Gs proteins leading to an increase in adenylate cyclase and 
consequentially a rise in cAMP. cAMP activates protein kinase A which 
phosphorylates several different proteins ultimately resulting in myosin 
light chain kinase inhibition and subsequent prevention of platelet granule 
secretion 47.  
 
1.4.6 Prostaglandin E1 (PGE1) 
 
PGE1 is produced in the body through the metabolism of 
dihomo-γ-linolenic acid by COX enzymes. PGE1 also binds to the IP 
receptor on platelets to again raise intracellular cAMP concentrations 
activate protein kinase A and to inhibit PLC activity to subsequently 
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reduce calcium release from intracellular stores 48,49. This prostanoid is a 
longer lasting inhibitor of platelet aggregation in vitro than PGI2.  
 
1.4.7 Apyrase  
 
The apyrase enzyme functions as a platelet inhibitor by facilitating the 
breakdown of ADP to AMP, thus preventing the proaggregatory effects of 









Figure 1.3 Platelet surface receptors and agonist activation 
pathways  
Figure showing the various mechanisms of platelet activation including 
agonists and their receptors as well as the site of action for common 
























1.5 Platelet RNA  
 
For decades it was generally thought that a platelet’s organelle, granule, 
protein and RNA content were all derived exclusively from the parent 
megakaryocyte and delivered to the platelet during its production. In 
addition due to lacking a nucleus platelets have no transcriptional abilities 
and their synthetic capabilities were assumed to be non-existent. As a 
consequence the studies of platelet RNA were greatly outnumbered by 
investigations focussed upon features of platelet biology, such as 
granules and surface receptors, which were more clearly associated to 
platelet function.   
 
However in more recent years, and linked to the advent of affordable next 
generation sequencing technologies, interest in platelet RNA has 
increased with investigators having now characterised platelet RNA in 
much finer detail, understanding better, it’s structure, regulation and 
fundamental role in protein synthesis.  
 
1.5.1 Platelet messenger RNA (mRNA)  
 
Messenger RNA (mRNA) is a subtype of RNA that is used as a single 
stranded template for the DNA from which it was transcribed. mRNA 
molecules are classically delivered from the nucleus of a cell to 
ribosomes within the cytoplasm to be translated into protein molecules. 
The complete set of expressed mRNAs belonging to a cell is called its 
transcriptome. Owing to the fact that they are anuclear the platelet 
transcriptome is largely derived from the megakaryocytes that produce 
them. In a study conducted by Cecchetti et al it was shown, using next 
generation RNA sequencing techniques and focussing upon examples 
from the matrix metalloproteinases family, that megakaryocytes 
selectively sort thousands of mRNA transcripts for transport into the 
platelet 52. Furthermore the abundance of a transcript in a megakaryocyte 
is not predictive of the abundance of that same transcript within the 
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platelet. As a consequence the platelet transcriptome is only a partial 
reflection of the megakaryocyte transcriptome.   
 
As expected of a cell lacking a nucleus, the quantity of mRNA within 
platelets is very small with estimates suggesting that a single platelet 
contains 10,000 times less mRNA than a single leukocyte 53.  Studies 
profiling the human platelet transcriptome have revealed that platelets 
possess a small but diverse range of 6000-10000 transcripts 54,55. 
Structurally platelet mRNAs closely resemble those of nucleated cells 
having both a 5’ 7-methylguanosine cap and a 3’poly(A) tail with 
polyadenylation sequences 56. mRNA translation is initiated when access 
to these structures is permitted by eukaryotic initiation factor-4E 57 and 
aided by mRNA binding proteins also found within the platelet 58.    
 
Not only do platelets contain mRNA they have also been shown to retain 
pre-mRNA and functionally critical components of a spliceosome, 
presumably accumulated during pro-platelet formation from 
megakaryocytes. A spliceosome is a complex molecular machine, 
associated with the nucleus, required to remove non-coding introns from 
pre-mRNA to produce translatable mRNA ready for transport into the 
cytoplasm 59. Despite lacking a nucleus this process has been shown to 
occur in platelets in a signal dependent manner in response to activating 
stimuli such as thrombin 60. This process is thought to be an important 
feature of platelet biology as it further enhances a platelet’s ability to 
diversify its functional properties.    
 
Following on from the production of mature mRNA, platelets are known to 
be capable of protein synthesis and to contain both ribosomes and rough 
endoplasmic reticulum. These observations were first made in the 1960s 
and 70s through experiments with radioactively labeled amino acids 61 
and electron microscopy 62. Improvements in protein separation 
techniques in the 1980s enabled investigators to show that platelets 
synthesized proteins including glycoprotein Ib, glycoprotein IIb/IIIa, 
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fibrinogen, albumin, thrombospondin and vWF 63. Such protein production 
is now known to occur in a signal dependent manner usually in response 
to an activating stimulus. In one example, Weyrich et al showed that 
platelets activated by thrombin translate B-cell lymphoma 3 mRNA into 
protein via mammalian target of rapamycin (mTOR) signaling pathways 
64. In addition this group was also the first to show that activated platelets 
possess the ability to use mRNA splicing events as a mechanism of 
regulating the synthesis of proteins including interleukin 1β and tissue 
factor 65. There is also some limited evidence supporting the idea that 
platelets continually produce protein throughout their lifespan even in the 
absence of agonist stimulation 66. Platelet biologists should consider 
these translational capabilities carefully as they reinforce the idea that 
platelets are important participants in more long-term cellular responses 
such as those contributing to immune responses.  
 
The quantity of megakaryocyte derived platelet mRNA declines 
throughout a platelets life span due to the fact that they lack the ability to 
transcribe new mRNA molecules. It has been estimated using in vivo 
studies that mouse platelet mRNA has a half-life of 6 hours with a 95% 
overall reduction in detectable cytoplasmic mRNA by 24 hours 67.  
Furthermore experiments using platelet like particles grown from human 
megakaryocytes in culture have been shown to contain mRNA which 
rapidly declines in concentration beginning at 4 hours post production and 
that this decay occurs with a half-life of 5.7 hours 68. Platelet mRNA 
decay is an interesting feature of platelet biology which can be used to 
investigate both platelet age and for the functional relevance of the 





1.5.2 Platelet microRNA (miRNA) 
 
In addition to mRNA platelets also contain a host of other functional and 
regulatory small non-coding RNAs including circular RNAs, YRNAs and 
microRNAs (miRNA), which may function to regulate platelet protein 
expression at the mRNA level. miRNAs are typically less than 22 
nucleotides in size and have been shown to regulate more than half of all 
human mRNAs either by enhancing translation, reducing translation or 
inducing degradation 69,70. Just like mRNAs, platelets obtain their miRNA 
repertoire from parent megakaryocytes during platelet formation 71. To 
date investigators have detected over 750 miRNAs within platelets which 
remain stable throughout its life-span in healthy control samples but 
which can be significantly altered in various disease states 72. Specific 
miRNAs have the ability to modify platelet function, for example 
miRNA-223 has been shown to bind to the 3’ untranslated region of 
human P2Y12 receptor mRNA where it could have the potential to 
regulate receptor expression and thus impact P2Y12 mediated platelet 
activity 73. Following on from this, reduced platelet miRNA-223 levels 
have been associated with high on clopidogrel (P2Y12 receptor 
antagonist) platelet reactivity 74,75.  
 
1.5.3 Functional relevance of platelet messenger and micro RNAs 
 
Having now firmly established that platelets possess a diverse and 
dynamic selection of micro- and messenger-RNAs, have a signal 
dependent system for protein translation and a mechanism for receiving 
select megakaryocyte derived transcripts platelet biologists are beginning 
to question the functional relevance of these RNA species.  
 
Advances in sequencing technologies have lead to the development of 
newer application such as RNA-Seq which supersede previous 
techniques such as Sanger sequencing, microarrays and qRT-PCR by 
enabling more precise detection of transcripts, without the need for a 
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reference genome, in a high-throughput and cost effective manner 76. In 
addition RNA-Seq requires a much smaller concentration of RNA, making 
it ideal for genetic studies of platelets. This technique enabled 
researchers to characterise and compare complete human and mouse 
platelet transcriptomes publishing them in 2011 as a public research tool 
54.  
 
A key question remains as to whether the platelet transcriptome is altered 
in disease states and what relevance this may have to the identification of 
novel biomarkers or therapeutic targets. In a study from Eicher et al the 
platelet transcriptomes belonging to patients with ST-segment elevation 
myocardial infarction (STEMI) versus non-STEMI (NSTEMI) patients 
were compared. The group identified over ninety differentially expressed 
genes between the two patient groups. In addition the study also 
identified genes linked to platelet aggregation in response to agonist 
stimulation with TRAP-6, collagen and ADP indicating that different 
activating signals have different impacts upon platelet gene expression 77.   
 
In a study using micro-array techniques Lood et al demonstrated that 
platelets taken from patients with systemic lupus erythematosus (SLE) 
expressed higher levels of both genes and proteins linked to the type-1 
interferon pathway. The investigators propose that these differences 
occur through the actions of interferon-α on megakaryocytes.  
Pro-inflammatory cytokines belonging to the type-1 interferon pathway 
have previously been linked to increased platelet aggregation and to the 
development of acute coronary syndromes. Patients with SLE have an 
increased risk of cardiovascular disease and thus the investigators 
proposed that platelet expression of type-1 interferon genes could be 
used as a novel biomarker for the development of cardiovascular disease 
in patients with SLE 78.  
 
Using platelets obtained from patients with sickle cell anemia researchers 
sought to investigate the link between thromboembolism/ 
hypercoagulability and sickle cell disease. By comparing the platelet 
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transcriptomes of those with sickle cell anemia to healthy controls the 
study revealed differential expressions for over 100 genes. Further 
pathway analysis indicated a global activation of genes involved in 
arginine uptake and catabolism. Arginine is converted to nitric oxide, an 
important platelet inhibitor and so if arginine catabolism is increased then 
this may provide a possible mechanism for the increased platelet 
reactivity and hypercoagulable state present in sickle cell anaemia 
patients 79.  
 
Platelets also possess the ability to transfer their nucleic acid material to 
other cell types. The group of Jane Freedman, for instance, showed using 
both in vitro and in vivo models that platelet-like particles produced from 
cultured megakaryocytes (MEG-01) transfer RNA to both monocytes 
(THP-1 cell line) and endothelial cells (HUVEC cell line) when 
co-cultured. Furthermore, they showed by transfecting MEG-01 cells with 
a GFP vector that PLP recipient cells received GFP both as a mature 
protein and mRNA that was subsequently translated 80–82. The authors of 
these studies suggest that such mechanisms of platelet RNA uptake 
provide novels mechanisms by which platelets may regulate vascular 
homeostasis and systemic immune responses. In another study using 
similar transfection and co-culturing techniques, investigators propose a 
mechanism of platelet-mediated liver regeneration which centres on the 
ability of hepatocytes to internalise platelets which then subsequently 
transfer functional RNA 83. 
 
Platelet miRNAs have also been shown in numerous investigations to 
regulate the expression of genes in other cells within the circulation 84. 
For example, platelet derived microparticles containing 
Argonaute 2/miRNA-223 complexes were shown to regulate the 
expression of mRNA and protein levels of two endothelial cell genes 
(FBXW7 and EFNA1) following internalisation 85,86. In a clinical study 
using RNA-Seq, Gidlof et al demonstrated that platelets from patients 
with myocardial infarction display a significant loss of eight miRNAs 
compared to control platelets. Furthermore they showed that miRNAs 
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shed from activated platelets can be taken up by endothelial cells to alter 
the expression of genes including ICAM1, an adhesion molecule 
mediating leukocyte-endothelial cell interactions 87.  
 
Additionally platelets also have the ability to uptake circulating RNA from 
other cell types.  This activity is currently being utilized in the field of 
cancer diagnostics where platelets have been shown to take up 
tumour-derived vesicles containing tumour specific RNA released into the 
circulation 88. Researchers have established a platelet RNA-Seq protocol 
enabling them to distinguish 228 patients with tumours from 55 healthy 
controls with 96% accuracy 89.  
 
Together these studies provide evidence for the ability of circulating 
platelets to change their transcriptomes in response to extracellular 
signalling in disease states and have helped to expand our knowledge of 
platelet thrombotic and non-thrombotic functions. Moreover, the research 
provides an interesting role for platelet RNA as a mediator of intracellular 
communication and proposes the use of platelet RNA as a diagnostic 








1.6 Newly formed, reticulated, platelets 
 
The total platelet population consists of multiple sub-populations each 
with distinct functional properties 91–93. Of particular interest to this thesis 
investigation is the newly formed, or reticulated, population owing to the 
fact that these platelets are thought to contain an abundance of 
megakaryocyte derived mRNA. The reticulated population is thought to 
account for just 10% of the total platelet population. This estimate is 
based on the knowledge that platelet lifespan is around 10 days and 
platelet mRNA half-life is around 12-24 hours 67. As such each day 10% 
of the platelet population is renewed 94. Consequently these newly 
formed reticulated platelets are sometimes referred to as immature 
platelets.   
 
The other defining feature of this platelet population is that they are 
thought to be more reactive than their non-reticulated counterparts and as 
such have been linked to multiple disease states. Notably, elevated 
populations of reticulated platelets have been linked to a higher incidence 
of acute coronary syndromes 95 as well as to high on treatment platelet 
reactivity in various patient groups receiving standard dual antiplatelet 
therapies 96,97. Indeed our own group has shown previously that, because 
of the short pharmacokinetic half-lives and single daily dosing of aspirin 
and thienopyridine antiplatelet therapies, there exists a point within the 
day that newly formed reticulated platelets emerge uninhibited. This 
highly reactive uninhibited platelet population then act as seeds for the 
formation of platelet aggregates 98. This study provides a possible cause 
for the lack of efficacy of antiplatelet therapies which could be particularly 
pertinent to patient groups known to have an increased platelet turnover 
as is seen in diabetes 99 and chronic kidney disease 100.  
 
Theses two defining features of reticulated platelets - increased reactivity 
and abundance of RNA – make this subpopulation interesting to 
researchers investigating the platelet transcriptome and the biological 
function of platelet RNA as well as to those looking to identify novel drug 
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targets or biomarkers of disease. The assessment of the reticulated 
platelet population is made possible by using either flow cytometry or the 
fully automated Sysmex haematological system. Both of these methods 
detect reticulated platelets based on the florescence intensity of nucleic 
acid binding dyes such as thiazole orange; reticulated platelets have 
abundance of cytosolic RNA and so will stain brightly with these dyes 
compared to other platelet populations 101. Flow cytometric 
measurements usually report reticulated platelet numbers within a 
predefined gate 102–104 whereas the Sysmex system reports reticulated 
platelets as the immature platelet fraction (%) or as the immature platelet 
count 105–107. The Sysmex system is used widely in clinical settings and in 
patient studies where it is favoured over flow cytometry owing to its 
standardisation, reproducibility, high throughput, efficiency and low cost.     
 
As the field moves forward it will be important to ascertain the cellular and 
molecular mechanisms linking reticulated platelets to pathological 








1.7 Platelet mediated bleeding disorders  
 
The term bleeding disorder is an umbrella term used to describe a group 
of conditions that share the common feature of inappropriate bleeding 
due to ineffective clot formation. Patients with bleeding disorders usually 
present with some or all of the following symptoms; bleeding into joints or 
soft tissue, menorrhagia, epistaxis, excessive bruising and extended 
bleeding after minor injuries, dental procedures or surgeries 108. Bleeding 
disorders are often inherited 109, however some can occur secondary to 
other conditions such as anaemia, liver cirrhosis, leukaemia, vitamin K 
deficiency or thrombocytopenia. Other bleeding disorders can occur as 
side effects caused by medications such as warfarin 110 and aspirin 111.   
 
Haemophilia (frequency of 1 in 10,000 in UK) 112,113 and von Willebrands 
disease (frequency of 1 in 100 in UK) 114 are the two most commonly 
diagnosed bleeding disorders and account for 95% of all inherited 
deficiencies of coagulation factors 115. Bleeding disorders attributable to 
defects in platelet function are considerably more rare and are often 
under-recognised due to difficulties in diagnosis. Platelet disorders are 
usually inherited in an autosomal recessive manner and present with 
milder symptoms of bleeding 116–119. The best characterised inherited 
platelet disorders are outlined in the following paragraphs. A list of all 
genes associated with inherited bleeding disorders can be seen in 
Table 1.3.  
	
Bernard Soulier syndrome is an inherited platelet disorder characterised 
by giant platelets, thrombocytopenia and prolonged bleeding time. This 
syndrome is caused by quantitative or qualitative defects in the 
glycoprotein Ib-IX-V complex that binds vWF. As a consequence this 
syndrome is often diagnosed by the absence of ristocetin induced platelet 
agglutination 120,121.   
 
Glanzmann thrombasthenia is a platelet surface receptor defect of 
glycoprotein IIb/IIIa (integrin α2bβ3) that mediates platelet interactions 
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with adhesive protein such as vWF and fibrinogen. As such the primary 
platelet defect is a reduction in platelet aggregate formation 122–124.  
Molecular defects to the P2Y12 receptor 125, TP thromboxane receptor 
and GPVI 126 and a2b1 collagen receptors have also been documented 
for a very limited number of cases 127.  
 
Wiskott-Aldrich syndrome is caused by mutations to the WAS gene which 
encodes for the WAS protein 128. This protein plays a key role in signal 
transductions processes in many cell types; as such symptoms of this 
syndrome are varied. The platelet dysfunction attributable to this 
syndrome is decreased aggregation in response to ADP, collagen and 
epinephrine as well as reduction in dense granule number 129,130.   
 
Storage pool disease is the collective term given to a number of platelet 
disorders featuring deficiencies of granule number, granule content and 
granule release resulting in reduced platelet aggregation. Grey platelet 
syndrome 131, Quebec platelet disorder 132, Paris-Trousseau syndrome 
133, Hermansky-Pudlak syndrome 134 and Chediak-Higashi syndrome 135 
are all examples of platelet storage pool disorders.    
 
Although the incidence of these syndromes is low, their characterisation 
has helped further our understanding of the molecular mechanisms 
supporting platelet function 136,137. Prior to the advent of DNA sequencing 
the gold standard assay for platelet function testing - light transmission 
aggregometry – was the most informative test used for the identification 
of platelet mediated bleeding disorders. In more recent years however 
advances in DNA and RNA sequencing technologies have significantly 
increased the rate of diagnosis of rare bleeding conditions. As a 
consequence large multicentre collaborative studies between clinicians 
and platelet biologists have been established to investigate links between 
bleeding phenotypes and genotypes 138–142. Three relevant examples of 
such studies are the ThromboGenomics study, the BRIDGE consortium’s 
bleeding and platelet disorders (BRIDGE-BPD) study and The 
Genotyping and Phenotyping of Platelets (GAPP) study. The 
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ThromboGenomics study uses a targeted approach for the identification 
of bleeding disorders associated to gene variants. This study recruits 
patients internationally but requires individuals who have a strong clinical 
phenotype for the 98 candidate gene approach to be informative 139. The 
BRIDGE-BPD study, setup by the NIHR as one of its rare diseases 
projects, aims to discover novel and established genetic variants linked to 
unexplained bleeding disorders 143. This study uses high throughput 
sequencing techniques to search for variants in a large cohort of patients 
recruited throughout the UK and in Europe. Similarly the GAPP study is a 
collaborative investigation carried out by research groups in Bristol, 
Nottingham and Sheffield who collect samples from patients referred to 
haemophilia care centres in the UK. Using whole exome sequencing and 
platelet phenotyping the study aims to discover causative variants in each 
individual recruited onto the study 140,141. Together such studies are 
helping to improve the lives of those living with bleeding disorders by 





























































Table 1.3 International Society of Thrombosis and Haemostasis list 
of genes linked to bleeding disorders 
 



































Platelets play an essential role in maintaining the fine balance between 
haemostasis and thrombosis within the human body. Tipping this balance 
in favour of thrombosis can result in myocardial infarction or ischemic 
stroke; two of the most common causes of death worldwide. As a 
consequence, great efforts have been made to understand better platelet 
biology with the hope of identifying novel therapeutic targets. Much of this 
work has focussed upon the characterisation of platelet receptors and 
their signalling pathways and many clinically approved antiplatelet 
therapies are based upon the inhibition of specific platelet surface 
receptors.  Other antiplatelet therapies target the signalling molecules 
produced by platelets and the intracellular pathways through which they 
act. 
 
Much research has focussed upon the mediators and pathways 
regulating platelet activation whereas until recently very little attention has 
been given to the role of RNA, mainly because platelets lack nuclei. 
However, in more recent years aided by advances in sequencing 
technologies investigators have begun to characterise the relatively small 
amounts of RNA within the platelet cytoplasm and to make associations 
between certain RNA species and disease outcomes.  
 
While laboratory research continues to delineate the many molecular 
controls of platelet function, cohorts of patients with bleeding disorders 
are being recruited into large multinational studies aiming to provide full 
genome sequencing for those patients. Not only will this provide patients 
with a genetic diagnosis for their bleeding symptoms but it will also shed 
light on the relationship between the platelet genotype and the platelet 
phenotype linking laboratory investigations to physiological function and 





1.9 Hypothesis and Aims  
 
This thesis will investigate the hypothesis that the characterisation and 
description of changes to genomic material, in the form of both platelet 
specific mRNA and as whole genomic DNA, coupled with in depth 
functional analyses can provide deeper definition of platelet reactivity, 
thrombotic risk and pro-thrombotic pathways.  
 
To that end the particular experimental aims are: 
1. To establish a robust protocol for the extraction of a pure platelet 
population from whole blood, taking into account the need to 
perform platelet function testing and RNA extraction. 
2. To further isolate newly formed reticulated platelets, using the 
most appropriate method established above, and to subsequently 
investigate their mRNA content and function.  
3. To obtain a platelet sample from a patient who has a mutation 
known to alter platelet function and to characterise those platelets 
in terms of function and mRNA content.  
4. To obtain blood and urine samples from families with known 
bleeding disorders, who have had their genomes sequenced, and 
provide in depth platelet function testing to understand better the 








Chapter 2 - Materials  
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384 wel qRT-PCR plate    Life Technologies, UK  
96 well flat-bottom half-area microtitre plates Fisher Scientific, UK 
Abscorbic acid      VWR, UK 
ABsolute qPCR ROX mix    ThermoScientific, UK 
Acid-citrate-dextrose     Sigma-Aldrich, UK 
Acrodisc syringe filter    Sigma-Aldrich, UK 
ADP       Labmedics, Salford, UK 
Agilent 2100 Bioanalyser    Agilent Technology, Germany 
Agilent 2200 Tapestation    Agilent Technology, Germany 
Alexa488 anti-mouse    eBioscience, UK 
Alexa647 anti-rabbit     eBioscience, UK 
Anti-human CD45 PerCP-Cyanine5.5  eBioscience, UK 
Anti-human CD61 FITC    eBioscience, UK 
Anti-human CD62 PE    eBioscience, UK 
Anti-mouse tubulin     Sigma-Aldrich, UK 
Anti-rabbit COX-1     New England Biolabs, USA  
Anti-human CD61 APC    eBioscience, UK 
Applied Biosystems ABI 7900HT instrument Agilent Technology, Germany 
Apyrase       Sigma-Aldrich, UK 
Arachidonic acid     Sigma-Aldrich, UK 
Automated pipetting system CAS-1200  Corbett robotics, UK 
BD FACSAria Fusion cell sorter    BD Biosciences, USA 
Bio/Data PAP-8E aggregometer   Alpha Laboratories, UK  
Bioshake plate IQ shaker    Quantifoil, Germany 
Bovine serum albumin    Sigma-Aldrich, UK 
CaCl2       Sigma-Aldrich, UK 
CellQuest software     BD Biosciences, USA 
Chart version 4.2 software    AD Instruments, UK 
Chronolume ATP     Labmedics, UK 
Chronolume luciferin-luciferase reagent   Labmedics, UK 
Chronolog 560C lumi aggregometer  Chronolog, USA 
Diclofenac      Barts Hospital Pharmacy, UK 
Donkey serum     Sigma-Aldrich, UK 
EDTA       Sigma-Aldrich, UK 
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Epinephrine      Labmedics, UK 
Ethanol       VWR, UK 
FACSCalibur flow cytometer   BD Biosciences, USA 
Fibrinogen      Sigma-Aldrich, UK 
Fix lyse solution      ThermoFisher Scientific, UK 
FlowJo software     TreeStar Inc, USA  
Formalin       Sigma-Aldrich, UK 
Gelatin      Sigma-Aldrich, UK 
Genome Suite software     Partek Inc, USA 
Glucose       Sigma-Aldrich, UK 
GraphPad Prism version 6 software   GraphPad Inc, USA 
Heparin      Sigma-Aldrich, UK 
HEPES      Sigma-Aldrich, UK 
Horm collagen suspension    Takeda, Linz, Austria 
Human serum albumin    Sigma-Aldrich, UK 
IBMX       Sigma-Aldrich, UK 
IDEAS software     Merck-Millipore, UK 
Illumina TopHat v2 software    Illiumina, Cambridge, UK 
Illumina Nextera XT Sample Kit   Illiumina, Cambridge, UK 
Illumina NextSeq®500 High-output kit  Illiumina, Cambridge, UK 
Illumina NextSeq sequencer    Illiumina, Cambridge, UK 
Imagestream X Mark II    Merck-Millipore, UK  
Isotonic glucose     Takeda, Linz, Austria  
KCl       Sigma-Aldrich, UK 
LD MACS separation columns    Miltenyi Biotec, Surrey, UK 
Lepirudin      Sigma-Aldrich, UK 
LSM 710 confocal microscope   Zeiss, Germany 
MACS beads anti-CD45    Miltenyi Biotec, Surrey, UK 
Methanol       VWR, UK 
MgCl2       Sigma-Aldrich, UK 
Na2HPO4      Sigma-Aldrich, UK 
NaCl       Sigma-Aldrich, UK 
Nanodrop 2000 spectrophotometer  ThermoScientific, USA 
Nanodrop 8000 spectrophotometer  ThermoScientific, USA 
 54 
Paraformaldehyde     VWR, UK 
PAXgene RNA tubes    PreAnalytiX, Switzerland 
PGE1       Sigma-Aldrich, UK 
Phosphate buffered saline (PBS)   Sigma-Aldrich, UK 
ProLong Diamond antifade mountant  ThermoFisher Scientific, UK 
Prostacyclin (PGI2) Enzo Life Sciences, UK 
PureLink RNA minikit    ThermoFisher Scientific, UK 
Qubit 2.0 Fluorometer    ThermoFisher Scientific, UK 
Ristocetin      Helena Biosciences, UK 
RNeasy minikit     Qiagen, UK 
Saline       Baxter, UK 
SDS qRT-PCR software     ThermoFisher Scientific, UK 
SMARTer cDNA synthesis kit   Clontech Laboratories, USA 
SuperScript III first-strand synthesis system  Life Technologies, UK 
TaqMan anti-human FAM-labelled probes Life Technologies, UK 
Tecan infinite® M200 plate reader   Tecan, Switzerland 
Tecan Sunrise plate reader   Tecan, Switzerland 
Thiazole orange     Sigma-Aldrich, UK 
TRAP-6 amide     Bachem, UK  
Tri-sodium citrate      Sigma-Aldrich, UK 
Triton        Sigma-Aldrich, UK 
TRIzol       ThermoFisher Scientific, UK 
U46619   Cayman Chemical, USA 










Chapter 3 - Comparison of protocols for the 
isolation of platelets from whole blood for 







Platelets whilst anucleate are now known both to contain transcriptional 
machinery, messenger RNAs and micro RNAs derived from their parent 
megakaryocytes and to be transcriptionally active (1). This recent 
realisation has encouraged studies to characterise platelet messenger 
and micro RNAs. However the low abundance of RNA within individual 
platelets and the contamination of samples with other cell types, in 
particular white blood cells (WBCs), present major complications for 
downstream RNA applications. Because of this there are many diverse 
protocols for the isolation of platelets from whole blood but currently no 
consensus as to which is best. In addition there is little information 
available regarding the choice of anticoagulant or blood collection method 
and whether this could impact measurements of platelet function.  
 
Within the blood platelets outnumber white blood cells (WBCs) 100 to 1.  
However, the RNA content of a white cell is much greater than that of a 
platelet with estimates being that a single WBC has 12,500 times more 
RNA than a single platelet 53. It is also worth noting that only about 10% 
of the total platelet population contains any RNA at all and those that do, 
have a relatively small selection of around 4000-5000 transcripts 54,55,145. 
Collectively, this makes detecting platelet specific RNA in whole blood 
technically challenging.  Despite these technical challenges, the adoption 
of newer transcriptome sequencing tools, including RNA-Seq, which 
circumvent the need for large RNA inputs have enabled the 
characterization of the platelet transcriptome in healthy volunteers 54,146. 
Moreover these techniques have facilitated the detection of changes to 
the platelet transcriptome in response to disease, most notably 
myocardial infarction 77. Other groups are investigating the link between 
platelet micro-RNA containing vesicles and cancer metastases 147. 
Together these studies have helped to reinforce the idea that platelet 
message, in the form of RNA expression, has valuable meaning, is 
relevant to multiple areas of research and could aid the discovery of novel 
biomarkers of disease 148.   
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In the studies outlined above, researchers have isolated pure platelet 
populations from whole blood using a variety of techniques, but there 
appears to be no agreement as to which is best.  The most suitable 
isolation method must take in to consideration not only the ability to 
remove contaminating blood cells but also the ability to minimise 
consequent platelet activation. For example syringe filtering of platelet 
rich plasma to remove WBCs requires the platelets to be forced through a 
filter under pressure.  The exposure of platelets to such forces may cause 
their activation, which could in turn bias towards a particular platelet 
sub-population or remove young platelets with an abundance of mRNA 
as they considered to be more reactive 149. Such activation events may 
therefore affect overall determinations of platelet RNA in individual 
samples. Moreover a suitable technique that is scalable to the large 
cohort sizes required in population studies would be particularly 
attractive.  
 
In this chapter I compare a range of platelet isolation protocols for their 
abilities to remove contaminating WBCs from platelet samples whilst 
minimising platelet activation.  
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3.2 Methodology  
 
3.2.1 Human blood collection  
 
St. Thomas’ Hospital Research Ethics committee approved all 
experiments using human blood  (reference, 07/Q0702/24). Volunteers 
gave written consent and were screened by obtaining measures of heart 
rate, temperature and blood pressure in conjunction with a medical 
history questionnaire. Donors were also required to have abstained from 
any pharmacological agents known to alter platelet function, must be 
non-smokers and must be under the age of 40.  
 
Blood samples were obtained by venepuncture of the antecubital vein 
into vacutainers or syringes loaded with tri-sodium citrate (3.2% w/v), 
acid-citrate-dextrose (ACD) or lepirudin (250 µg/mL) to achieve an 
anticoagulant to whole blood ratio of 1:9. For whole blood RNA analyses 
blood samples were taken directly into a PAXgene Blood RNA tubes. 
 
3.2.2 Preparation of platelet rich plasma (PRP) and platelet poor 
plasma (PPP) 
 
Whole blood samples were centrifuged at 175 x g for 15 min at 25°C to 
produce PRP which was then kept in the water bath at 37°C until use. 
PRP was further centrifuged at 12000 x g for 2 min at 25°C to obtain PPP 




Figure 3.1 Centrifugation of whole blood 
 
Schematic diagram outlining the process of centrifuging whole blood to 




3.2.3 Preparation of washed platelets  
 
PRP was centrifuged with the addition of PGI2 (2 µg/ml) and apyrase 
(0.02 U/ml), at 1000 x g for 10 min resulted in a platelet pellet that was 
re-suspended in modified Tyrode’s-HEPES buffer (NaCl, 134 mM; KCl, 
2.9 mM; Na2HPO4, 0.34 mM; NaHCO3, 12 mM; HEPES, 20 mM; MgCl2, 
1 mM), supplemented with glucose (0.1% w/v), bovine serum albumin 
(BSA; 0.35% w/v) and apyrase (0.02 U/ml). PGI2 (2 µg/ml) was added 
and the platelets were centrifuged again at 1000 x g for 10 min. 
Supernatant was removed and the pellet was resuspended in modified 
Tyrode’s-HEPES buffer to yield washed platelets.   
 
3.2.4 Preparation of syringe filtered platelets  
 
Apyrase (0.02 U/mL) was added to a volume of washed platelets which 
were then loaded into a syringe and forced, by hand, through an 5 µm 
Acrodisc® syringe filter.   
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3.2.5 Preparation of magnetically activated cell sorted (MACS) 
platelets  
 
Washed platelets were incubated with (MACS + beads) or without 
(MACS - beads) anti-CD45 magnetic beads for 15 min at 4°C. LD MACS 
separation columns were mounted on a MACS separation stand and 
primed with MACS buffer before the platelets were added. The washed 
platelets were then passed through these columns twice and the 




Figure 3.2 Magnetic activated cell sorting of platelets 
 
A schematic diagram showing the labelling and processing of PRP to 





Cells in platelet rich 
plasma are incubated 
with anti-CD45 
magnetic beads 
Cells are passed 
through the 
magnetic column 
twice into a 
collection tube 
Collection tube will 
contain all CD45 
negative cells (platelets) 
The magnetic field 
placed around the 
column will cause 
CD45 positive events 
to bind to the column 
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3.2.6 Light transmission aggregometry (LTA) 
 
LTA is considered to be the gold standard for platelet aggregation testing. 
It is based upon the principles first outlined by Gustav Born in the 1960s 
150. In this study 225 µL of PRP was added to each cuvette that was then 
placed in one of eight channels in a Bio/Data PAP-8E turbidometric 
aggregometer. PRP was stirred, by placing a stir bar in the bottom, and 
incubated at 37°C. All channels were blanked using a cuvette containing 
250 µL PPP and a stir bar. 25 µL of agonist at 10 times the final required 
concentration was added to the appropriate PRP containing cuvettes. 
PBS was used as a diluent for ADP and TRAP-6 amide, isotonic glucose 
for collagen, and 0.1% ascorbic acid/PBS for arachidonic acid. When 
agonists were added causing the platelets to aggregate the platelet 
suspension became less turbid, decreasing light scatter and thus 
increasing light transmission as detected by the photocell. 
 
3.2.7 Optimul plate assay 
 
Flat-bottom half area microtitre plates were precoated with hydrogenated 
gleatin in PBS before the addition of agonists. Agonists used were ADP 
(0.005-40 µM), epinephrine (0.0004-10 µM), TRAP-6 amide (0.03-40 µM), 
U46619 (0.055-40 µM), arachidonic acid (0.03-40 µM), ristocetin 
(0.14-4 mg/mL) and Horm collagen (0.01-40 µg/mL). 5 µL of agonist was 
added to its corresponding well. The plates were then placed in a -80°C 
freezer for 1 hour before being put into a freeze-dryer at -40°C and left 
overnight. Plates were then vacuum-sealed and wrapped in aluminum foil 
until required 151 (Figure 3.3). Upon use, 40 uL of PRP or PPP was added 
to the appropriate wells, the plate were shaken on a Bioshake plate 
shaker at 1200 rpm, for 5 min at 37°C and the absorbance was read at 






















Figure 3.3 Example Optimul plate setup 
Agonists freeze dried onto plate in columns 2-8. Column 1 A-D contain 




3.2.8 Flow cytometry quantification of white blood cell 
contamination 
  
To quantify white blood cell (WBC) contamination samples were 
incubated with anti-human CD45 PerCP-Cyanine5.5 (1:60) to identify 
WBCs and anti-human CD61 APC (1:25) to identify platelets. Both 
antibodies were diluted in saline and samples were incubated for 30 min 
in the dark at 4°C and fixed in 990 µL 1% formalin in saline. Data was 
then acquired on a FACSCalibur flow cytometer using CellQuest 
software. CD45-positive events were recorded and expressed per 
100,000 CD61-positive events using FlowJo software.  








































3.2.9 Flow cytometric assessment of platelet activation 
  
To assess platelet activation, platelet preparations (PRP, washed 
platelets, or FACS sorted platelets) were stimulated with TRAP-6 25 µM 
and shaken in a 96-well plate at 1200 rpm for 5 min or left untreated for 
measurements of basal activation. Samples were then incubated for 30 
min in the dark at 4°C with CD61 APC (1:160) as the platelet identifier 
and CD62P PE (1:80) as the indicator of activation, and then fixed using 
500 µL 1% formalin in saline. Flow cytometry was then used to quantify 
either the number of CD62P positive events per 100,000 CD61 positive 
events or to obtain mean fluorescence intensity values for the total 
CD62P positive events. Data was acquired on a FACSCalibur flow 
cytometer using CellQuest software.  
 
3.2.10 Whole blood RNA extraction  
 
2.5 mL of blood was collected directly into PAXgene Blood RNA tubes 
containing 6.9 mL of reagent designed to lyse all cell types, prevent 
ex vivo gene regulation events and protect RNA molecules from RNase 
and other enzymatic degradation processes. The stabilisation of RNA 
molecules allowed samples to be frozen at -80°C for up to 96 months.  
 
Prior to RNA extraction PAXgene Blood Tubes containing sample were 
removed from the -80°C freezer and left to thaw at room temperature for 
a minimum of 2 hrs. The tubes were then spun at 4000 x g for 10 min, the 
supernatant removed and pellet resuspended in RNase free water before 
being spun again at 4000 x g for 10 min. The pellet was then 
resuspended in optimised buffers and proteinase K to enable protein 
digestion. Samples were then centrifuged through a shredder spin 
column to remove debris. 350 µL ethanol was then added to the flow 
through to enable binding when placed into an RNA spin column. When 
centrifuged inside this spin column RNA selectively binds to the silica 
membrane whereas contaminants are washed through. A series of wash 
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steps were then implemented to further remove any contaminants. 
DNase I was added between washes to remove any remaining DNA. 
After washing RNA was eluted from the silica membranes with the 
addition of elution buffer. RNA was finally denatured by heating to 65°C 
for 5 min and stored at -20°C until required for its downstream 
applications. All reagents and materials were supplied in the PAXgene 
Blood RNA kit.   
 
3.2.11 Platelet RNA extraction 
  
RNA was extracted from platelets using the RNeasy mini kit and the 
protocol was based on manufacturers instructions. Centrifuging PRP at 
1000 x g rpm for 10 min pelleted platelets, the supernatant was 
discarded. The cell pellet was then resuspened in 350 µL Buffer RLT, the 
pellet was disrupted by pipetting. This was then centrifuged for 3 min at 
15000 x g. Supernatant was removed and to it 350 µL 70% ethanol was 
added to optimise binding conditions. 700 µL of the sample was 
transferred into an RNeasy Mini spin column containing the silica 
membrane to which the RNA binds, placed in a 2 mL collection tube and 
centrifuged for 1 min at 15000 x g. The flow through was discarded.  
700 µL of Buffer RW1 was then added to the membrane and centrifuged 
as in the previous step. The flow through was discarded.  500 µL Buffer 
RPE was then added to the membrane and centrifuged as in the previous 
step, this was repeated twice. The spin column was then placed in a new 
2 mL collection tube and spun for 1 min at 15000 x g to dry the 
membrane. To finally elute the RNA, the spin column was place into a 
new 2 mL collection tube, 30 µL of RNase free water was added and the 
column was spun for 1 min at 15000 x g. RNA was stored at -80°C until 





3.2.12 cDNA synthesis 
 
cDNA was synthesised from the extracted RNA using SuperScript III 
first-strand synthesis system for RT-PCR. Each sample had its own 
reaction tube. To these nuclease free-micro centrifuge tubes 8 µL of 
RNA, 1 µL of 50 µM oligo(dT) and 1 µL of 10 mM dNTP mix was added. 
The tubes were then incubated at 65°C for 5 min before being placed on 
ice for 5 min. To each of these tubes 10 µL of cDNA synthesis mix was 
added. cDNA synthesis mix was composed of 2 µL 10X RT buffer, 4 µL 
25 mM MgCl2 , 2 µL 0.1 M DTT, 1 µL 40 U/µL RNaseOUT, 1 µL 200 U/µL 
SuperScript III RT. The tubes were then incubated at 50°C for 50 min 
followed by 85°C for 5 min before then being chilled on ice. 1 µL of 
RNase H was then added to each tube and incubated at 37°C for 20 min. 
cDNA was stored at -20°C until required.    
 
3.2.13 Nanodrop quantification of RNA concentration  
 
RNA concentrations were determined using the Nanodrop 2000 
spectrophotometer. Prior to sample loading the instrument was cleaned 
and blanked against a deionised water control. 1 µL of RNA sample was 
pipetted onto the lower optical pedestal allowing the software to 
automatically calculate the RNA concentration.    
 
3.2.14 Quantitative real tme PCR (qRT-PCR) 
 
Target genes were rationally selected as candidates based on their 
associations to either white blood cells (ANPEP, PTPRC, MPO) or 
platelets (GP6, PF4, P2RY12). House keeping genes used were ACTB, 
TUBB1, 18S and GAPDH. TaqMan anti-human FAM-labelled probes 
were obtained from Life Technologies (ANPEP, Hs00174265_m1; 
PTPRC, Hs04189704_m1; MPO, Hs00924296_m1; GP6, 
Hs00212574_m1; PF4, Hs00427220_g1; P2RY12, Hs01881698_s1; 
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ACTB, Hs01060665_g1; TUBB1, Hs00258236; 18s, Hs99999901_s1 and 
GAPDH, Hs02758991_g1). 
 
8 µL of the probe containing mix of 55 µL gene specific TaqMan probe, 
295 µL of RNase free water and 550 µL of ABsolute qPCR ROX mix plus 
2 µL cDNA were added to each well of a 384 well qPCR plate using an 
automated pipetting system. qRT-PCR was performed on a Applied 
Biosystems ABI 7900HT instrument. The cycle consisted of an initiation 
phase of 15 min at 95°C, followed by an amplification phase of 15 sec at 
95°C then 1 min at 60°C for 40 cycles and then a dissociation phase of 
15 sec at 95°C followed by 15 sec at 60°C followed by 15 min at 95°C. 
Data was collected using SDS software and analysed using the formula 
2^-(GEOMEAN (composite Ct of platelet genes) – GEOMEAN (composite 
Ct of white blood cell genes). An example of how Ct values are derived 





Figure 3.4 Hypothetical amplification plot 
Hypothetical amplification plot showing how Ct values are obtained. The 
Ct value of a particular gene corresponds to the number of cycles it takes 
for that gene’s fluorescence signal to surpass an arbitrary threshold set 
by the analysis software. From this example there is a three cycle 
difference between the pink and blue genes 152.  
 
 
3.2.15 Statistical analysis 
 
All statistical analyses were conducted used GraphPad Prism v6 and 




3.3.1 Assessing the impact of anticoagulants and blood collection 
methods on platelet aggregation using traditional light transmission 
(LTA) aggregometry and the Optimul plate assay 
 
A blood sample was collected by venepuncture into either a syringe or 
vacutainer containing the anticoagulants ACD, lepirudin or citrate. PRP 
was produced from these samples and platelet responses assessed 
using LTA and the Optimul plate assay. In traditional LTA experiments 
there was no significant difference between syringes versus vacutainers 
(Figure 3.5) or between ACD versus lepirudin versus citrate (Figure 3.6) 
for any of the agonists used: AA 1 mM (A), ADP 20 µM (B), collagen 10 
µg/mL (C) or TRAP-6 25 µM (D). In the Optimul plate assays there were 
no significant differences between responses of platelets collected in 
different anticoagulants in either syringe (Figure 3.7) or vacutainer 
(Figure 3.8) for the agonists AA (A), ADP (B), collagen (C), epinephrine 
(D), ristocetin (E), TRAP-6 (F) or U46619 (G) at multiple concentrations. 
Log EC50 values and the 95% confidence intervals of the log EC50 
values can be seen for the syringe collected samples in Table 3.1 and for 
vacutainer collected samples in Table 3.2. Non-linear regression curves 
were fitted using GraphPad Prism software for each agonist using the 
following constraints; bottom ≥ 0 and top ≤ 100.  
 
Comment on the fact that all the ‘not calculated’ 95% confidence interval 
values occurred exclusively in the lepirudin samples indicating the lack of 






Figure 3.5 The effects of syringe versus vacutainer blood collection 
on platelet aggregation assessed using LTA  
 
LTA aggregation data presented as final percentage aggregation. Results 
displayed as mean ± SEM (n=4). Significance was assessed using a 








































































































































































































































































































































































































Figure 3.6 The effects of different anticoagulants on platelet 
aggregation assessed using LTA  
 
LTA aggregation data presented as final percentage aggregation. Results 
displayed as mean ± SEM (n=4). Significance was assessed using a 






























































































































































































































































































































Figure 3.7 The effects of different anticoagulants on platelet 
aggregation assessed by the Optimul plate assay - syringe collected 
blood 
Optimul plate platelet aggregation data presented as percentage 
aggregation for PRP samples obtained from syringe collected whole 
blood. Results displayed as mean ± SEM (n=4). Significance was 
assessed using a two-way ANOVA and Tukey’s multiple comparisons 
test (p=<0.05).  
 





















































































































Figure 3.8 The effects of different anticoagulants on platelet 
aggregation assessed by the Optimul plate assay – vacutainer 
collected blood  
Optimul plate platelet aggregation data presented as percentage 
aggregation for PRP samples obtained from syringe collected whole 
blood. Results displayed as mean ± SEM (n=4). Significance was 
assessed using a two-way ANOVA and Tukey’s multiple comparisons 
test (p=<0.05).  























































































































Table 3.1 Optimul data log EC50 values and 95% confidence 
intervals – syringe collected blood 
Log EC50 values and 95% confidence intervals for the non-linear 
regression curves fitted to the Optimul data assessing effects of different 





Arachidonic	acid	 ACD -3.30 -3.645 to -2.958
Citrate -3.19 -4.681 to -1.696
Lepirudin -3.50 Not calculated
ADP ACD -5.32 -5.485 to -5.152
Citrate -5.49 -5.661 to -5.315
Lepirudin -5.45 -5.909 to -4.999
Collagen ACD -6.60 -6.807 to -6.384
Citrate -6.80 -7.061 to -6.529
Lepirudin -6.83 Not calculated
Epinephrine ACD -6.95 -7.251 to -6.650
Citrate -6.86 -7.266 to -6.447
Lepirudin -7.16 Not calculated
Ristocetin ACD -3.21 -3.288 to -3.137
Citrate -3.22 -3.281 to -3.167
Lepirudin -3.14 Not calculated
TRAP-6 ACD -6.18 -6.520 to -5.831
Citrate -6.16 -6.465 to -5.861
Lepirudin -6.71 -6.904 to -6.509
U46619 ACD -6.48 -6.686 to -6.276
Citrate -6.87 -7.145 to -6.603




Table 3.2 Optimul data log EC50 values and 95% confidence 
intervals – vacutainer collected blood 
Log EC50 values and 95% confidence intervals for the non-linear 
regression curves fitted to the Optimul data assessing effects of different 






Arachidonic	acid	 ACD -3.49 -3.519 to -3.453
Citrate -3.28 -4.436 to -2.128
Lepirudin -3.29 -3.810 to -2.777
ADP ACD -5.28 -5.496 to -5.070
Citrate -5.34 -5.633 to -5.048
Lepirudin -5.41 -5.814 to -5.006
Collagen ACD -6.05 -6.232 to -5.873
Citrate -6.27 -6.425 to -6.113
Lepirudin -6.86 Not calculated
Epinephrine ACD -6.78 -7.081 to -6.477
Citrate -6.88 -7.240 to -6.520
Lepirudin -7.47 -7.943 to -7.004
Ristocetin ACD -3.26 -3.365 to -3.160
Citrate -3.14 -3.217 to -3.061
Lepirudin -3.33 Not calculated
TRAP-6 ACD -5.96 -6.141 to -5.769
Citrate -5.98 -6.073 to -5.881
Lepirudin -6.25 -6.376 to -6.118
U46619 ACD -6.56 -6.818 to -6.299
Citrate -6.64 -6.838 to -6.440
Lepirudin -6.98 -7.529 to -6.435
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3.3.2 Assessing the impact of anticoagulants and blood collection 
methods on platelet activation by flow cytometric analysis of 
P-selectin expression 
 
In addition to measures of platelet aggregation, platelet activation in 
response to the three anticoagulants and the syringe or vacutainer 
collected blood samples was measured by quantifying platelet surface 
expression of P-selectin (CD62P) using a flow cytometric assay. There 
was no significant difference between syringes versus vacutainers for 
either PBS vehicle treated PRP or TRAP-6 (25 µM) stimulated PRP 
(Figure 3.9) or between ACD versus lepirudin versus citrate 
anticoagulants (Figure 3.10). 
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Figure 3.9 The effects of syringe versus vacutainer blood collection 
on platelet activation 
  
Flow cytometric analysis comparing platelet surface P-selectin (CD62P) 
expression for PBS (A,C,E) or TRAP-6 (25 µM) (B,D,F) treated PRP. 
Data presented as mean fluorescence intensity of P-selectin. Results 
displayed as mean ± SEM (n=4). Significance was assessed using a 





















































































































































































































Figure 3.10 The effects of different anticoagulants on platelet 
activation 
  
Flow cytometric analysis comparing platelet surface P-selectin (CD62P) 
expression for PBS (A,B) or TRAP-6 (25 µM) treated (C,D) PRP. Data 
presented as mean fluorescence intensity of P-selectin. Results displayed 
as mean ± SEM (n=4). Significance was assessed using a one-way 




































































































































































3.3.3 Selection of appropriate antibody dilutions for the 
identification of platelets and WBCs in PRP samples 
 
In order to maximise target identification and to minimise off target 
binding when using antibodies in flow cytometric assays it was important 
to first test a range of antibody dilutions from which optimal dilutions could 
be selected.  
 
CD61 APC was used as the platelet specific identifier at a dilution range 
of 1:20, 1:25, 1:40 and 1:80 (Figure 3.11 A-B). CD45 PerCP-Cyanine 5.5 
was used as the white blood cell specific identifier at a dilution range of 
1:30, 1:60, 1:120, 1:160 (Figure 3.11 C-D). Isotype controls were used to 
identify non-specific binding. Based on sufficient difference between the 
isotype control signals, CD61 APC at a dilution of 1:25 and CD45 
PerCP-Cyanine 5.5 at a dilution of 1:60 were selected as appropriate 









Figure 3.11 Flow cytometric histograms used to identify appropriate 
antibody dilutions 
 
Representative histograms (A,C) and bar charts (B,D) showing mean 
fluorescence intensity of CD61 APC or CD45 PerCP-Cyanine 5.5 across 





























































































3.3.4 Flow cytometric gating strategies for platelets and WBCs in 
whole blood or PRP samples 
 
Antibodies for CD61 and CD45 were used to identify platelets 
(Figure 3.12 B and E) and white blood cells (Figure 3.12 C and F) 
respectively in samples of either whole blood (Figure 3.12 A-C) or PRP 
(Figure 3.12 D-F). Gating was based on side scatter and forward scatter 
or by fluorescence intensity of the identifying antibody. The cell 
populations of interest are shown inside the pink shapes.  
 
Sample acquisition stop gates we set at either 100,000 or 1,000,000 
CD61 positive events and the percentage of CD45 positive events were 
recorded for each. There was no significant difference in the percentage 
of CD45 positive events between samples containing 100,000 versus 
samples containing 1,000,000 CD61 positive events showing that 
acquiring 100,000 CD61 positive events is sufficient for accurate 









Figure 3.12 Identifying platelets and WBCs in whole blood and PRP 
using flow cytometry 
 
Representative pseudo-colour plots showing the cellular populations 
present in both whole blood samples (A-C) or in PRP samples (D-F). 
Platelets were identified using CD61 APC. WBCs were identified using 
CD45 PerCP Cyanine 5.5. Pseudo-colour plots created using FlowJo 














Figure 3.13 Assessing the percentage of CD45 positive events when 
capturing 100,000 or 1,000,000 CD61 positive events  
 
Flow cytometric analysis comparing the percentage of CD45 events in 
PRP samples where either 100,000 or 1,000,000 CD61 positive events 
were captured. Results displayed as mean ± SEM (n=10). Significance 































3.3.5 Flow cytometric assessment of WBC contamination for each 
platelet isolation method    
 
Platelets were isolated from whole blood using various isolation protocols 
as outlined in Methods 3.2.2-3.2.5. Populations were gated to capture 
total CD45 positive events. Each isolation method showed significant 
reductions in CD45-positive events compared to whole blood. In freshly 
collected blood there were 2416±210 CD45-positive events per 100,000 
platelets.  All platelet isolation methods produced marked reductions in 
CD45-positive events (Figure 3.14): PRP 41±6; washed platelets 59±12, 
washed platelets plus syringe filter 57±12; MACS minus beads, 37±7; 
MACS plus beads, 36±10 (per 100,000 platelets). No significant 





Figure 3.14 FACS quantification of WBC contamination 
 
FACS analysis showing the number of total CD45 positive events per 
100,000 CD61 positive events in whole blood, platelet rich plasma (PRP), 
washed platelets, washed platelets passed through a syringe filter, PRP 
through MACS columns without CD45 magnetic beads, and PRP through 
MACS columns with CD45 magnetic beads. Results displayed as 
mean ± SEM. A one-way ANOVA with Tukeys multiple comparisons test 

































































3.3.6 Nanodrop quantification of RNA concentration obtained using 
various RNA extraction kits 
 
RNA was extracted from 25-35 mL of PRP obtained from 100 mL of 
whole blood and pelleted by centrifugation with PGI2. Three commercially 
available RNA extraction kits were compared for RNA concentration 
following extraction measured using the Nanodrop 2000 
spectrophotometer. There was no significant difference between the three 
kits tested (Figure 3.15). As a consequence the RNeasy minikit was used 






Figure 3.15 Comparison of commercially available RNA extraction 
kits 
 
Nanodrop quantification of RNA concentrations extracted from PRP using 
the RNeasy mini kit, PureLink RNA mini kit and the PureLink RNA mini kit 
plus a TRIzol lysis step. Results displayed as mean ± SEM (n=6). A 
one-way ANOVA with Tukey’s multiple comparisons test was used to 




























3.3.7 Optimising minimum PRP volumes for subsequent RNA 
analysis 
  
In many situations access to patient or healthy volunteer blood samples 
are limited due to ethical restrictions. For this reason it is important to 
determine the minimum volume of PRP required for RNA extraction and 
the production of reliable signals using downstream applications such as 
qRT-PCR. Figure 3.16 shows that as the volume of PRP increases the 
average Ct value of each gene decreases. The greater the Ct value the 






Figure 3.16 qRT-PCR analysis of abundant platelet genes in RNA 
samples extracted from a range of PRP volumes  
 
qRT-PCR analysis comparing the mean Ct values for three genes which 
are abundant in platelets; ITGA2B, PF4 and TUBB1 for RNA extracted 
from 0.2 mL, 0.5 mL, 1.0 mL, 2.5 mL and 5 mL PRP. Each gene was run 
in triplicate. Results displayed as mean ± SEM (n=3). A one-way ANOVA 
for each individual gene with Tukeys multiple comparisons test was used 



























































































3.3.8 qRT-PCR assessment of WBC contamination for each platelet 
isolation method    
 
The qRT-PCR data further supports the results generated by flow 
cytometry. Data shows that all platelet isolation protocols significantly 
increase the expression of platelet specific genes (composite measure of 
P2RY12, PF4 and GP6 mRNA levels) in comparison to whole blood 
(Figure 3.17). The greatest change occurs between whole blood and PRP 
showing a 554-fold increase in platelet specific gene expression 
compared to white blood cell specific gene expression (Table 3.3). Ct 





Table 3.3 Summary of qRT-PCR data comparing expression of 
platelet specific genes to WBC specific genes 
Table comparing the fold change in the ratio of platelet specific to WBC 
specific gene expression. Values were then compared to the fold change 
in relation to whole blood and again to the fold change in comparison to 









Whole	blood N/A N/A 24.4
PRP 554 N/A 30.0
Washed	platelets 2010 3.6 29.0
WP+syringe	filtering 3635 6.6 34.1





Figure 3.17 qRT-PCR data comparing expression of platelet specific 
genes to WBC specific genes 
 
qRT-PCR data plotting the ratio of platelet specific gene expression 
(GP6, PF4, P2RY12) to WBC specific gene expression (ANPEP, MPO, 
PTPRC). Results were calculated using the formula 2^-(GEOMEAN 
(Platelet markers)-GEOMEAN (WBC markers)) and significance 
assessed using column statistics with a one sample t-test comparing all 
extraction methods to whole blood which was set as the hypothetical 

























































2^-(GEOMEAN (Platelet genes) - GEOMEAN 






Table 3.4 qRT-PCR data comparing individual gene expression of 
platelet specific genes to WBC specific genes 
 
Table of raw Ct value data used to generate Figure 3.17. Data table 
shows the average Ct values for each of the six individual genes used in 
the calculation 2^-(GEOMEAN (Platelet markers)-GEOMEAN (WBC 





















Whole	blood 26.2 32.2 31.6 26.0 32.7 24.4
PRP 22.4 30.1 29.4 33.5 38.9 30.0
Washed	platelets 21.7 28.2 28.1 34.2 37.5 29.0
WP+syringe	filtering 23.9 30.9 30.5 39.2 39.6 34.1
WP+MACS 24.7 31.1 30.9 39.7 39.4 36.1
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3.3.9 Assessing the impact of each isolation technique on platelet 
activation 
 
To assess the impact of the isolation methods on platelet activation 
levels, flow cytometry was used and the expression of CD62P upon the 
platelet surface, as an indicator of P-selectin expression and platelet 
activation, was measured. Syringe filtering of washed platelets 
(mean=43003) induced significantly higher CD62P expression on 








Figure 3.18 FACS analysis quantification of platelet activation 
 
FACS analysis data of the number of CD62P positive cells found 
following different isolation methods per 100,000 CD61 positive events. 
Results displayed as mean ± SEM (n=8). A one-way ANOVA with 


































































Ex vivo and in vitro investigations of platelet function rely fundamentally 
on the ability to obtain an anticoagulated blood sample. The choice of 
anticoagulant used is key; the chosen agent must prevent the formation 
of a blood clot whilst preserving platelet function. Furthermore platelets 
are readily activated during the blood sampling procedure and so the 
selection of needle gauge, tourniquet release point and receptacle into 
which the blood is taken must be considered carefully in respect to the 
specific aspects of platelet function being investigated.   
 
The inter-laboratory variability and lack of agreement on a standardised 
blood taking protocol for the assessment of platelet function in platelet 
rich plasma makes comparisons of data generated by different research 
groups challenging 153.  
 
In this chapter I compared the use of three anticoagulants commonly 
used to study platelet function in PRP; acid-citrate-dextrose (ACD), 
lepirudin and sodium citrate. ACD and sodium citrate function as 
anticoagulants by chelating extracellular calcium. Calcium is an essential 
cofactor required for multiple processes occurring as part of the 
coagulation cascade. A drawback to using this type of anticoagulant is 
that calcium is also essential for platelet secretion and aggregation 
responses, thus calcium depletion may lead to altered in vitro reactivity 
154. In contrast lepirudin, a yeast derived recombinant version of hirudin, 
functions as an anticoagulant by acting as a direct thrombin inhibitor thus 
preventing the conversion of fibrinogen to fibrin in the coagulation 
cascade and inhibiting PAR activation. In studies performed using assays 
to examine platelet function in whole blood it has been reported that 
platelet aggregation was significantly impaired in citrated blood compared 
to samples containing thrombin inhibitors 155,156. However supporting 
evidence in assays using PRP is lacking.  According to results from a 
worldwide survey on the assessment of platelet function testing 
conducted by the International Society on Thrombosis and Haemostasis 
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99% of platelet testing laboratories surveyed used sodium citrate as their 
routine anticoagulant 157.   
 
In addition I also compared the use of either syringe or vacutainer 
collection of blood samples. Advantages of using a syringe include being 
able to take a large volume of blood into a single container, being able to 
change the rate at which blood is collected and being able to alter the 
concentration of anticoagulant loaded into the syringe. Advantages of 
using a vacutainer include standardisation of anticoagulant concentration 
and blood volume, lower risk of contamination, exposure of blood to a 
consistent force and being simple to use 158.  
 
Together I assessed these five blood collection variables in terms of their 
abilities to effect platelet aggregation, as measured using LTA 
(Figure 3.5 and Figure 3.6) and the Optimul assays (Figure 3.7 and 3.8), 
and platelet activation measured using a flow cytometric assay 
(Figure 3.9 and 3.10). I found that there was no significant difference 
between any of the combinations of anticoagulants or blood taking 
receptacles investigated within any of the assays used. Furthermore 
analysis of the 95% confidence intervals of the EC50 values calculated 
for each agonist response curve revealed large and in some cases 
incalculable ranges for many of the lepirudin samples (Table 3.1 and 3.2). 
Such large variability makes this the use of this anticoagulant unsuitable 
for experiments with small sample sizes. Therefore I collected future 
blood samples into sodium citrate filled syringes unless stated otherwise. 
 
The ability to obtain a pure platelet population from freshly collected 
whole blood is essential for downstream platelet RNA expression 
analyses and for platelet function testing. This chapter compared the 
ability of four typically used methods to remove contaminating WBCs 
from isolated platelets. I found that there was a large reduction in both 
WBC number, as assessed using flow cytometric techniques 
(Figure 3.14), and WBC specific mRNA expression (Figure 3.17), as 
assessed by qRT-PCR, when comparing PRP to whole blood. This 
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reduction was noted as a more than 500-fold enrichment of platelet 
mRNA relative to WBC mRNA when comparing PRP to whole blood 
(Table 3.3). There was a further 6.6-fold enrichment by the use of 
subsequent syringe filtration (Table 3.4). However, there was a concern 
that this more robust physical manipulation of platelets could cause 
stimulation. This platelet stimulation could lead to activation of platelet 
transcription and/or selective activation and loss of particular platelet 
subpopulations that would confound analyses. To assess this possibility 
measurements of platelet surface expression of CD62P as a marked of 
platelet activation were made. Notably, this was unchanged between 
PRP and whole blood but was markedly increased in syringe filtered 
washed platelets (Figure 3.18).  
 
In summary, the choice of anticoagulant or blood taking receptacle has 
negligible effect on measurements of platelet function including 
aggregation and activation. In addition, simple centrifugation of whole 
blood to obtain PRP is effective at reducing WBC contamination by a 
factor of around 500-fold. Additional steps of syringe filtering or magnetic 
cell separation provide at best a further 10.9-fold enrichment.  However, 
these approaches introduce a very marked increase in sample 
preparation time and the potential for platelet activation. The simple 
production of PRP requires much less labour and expense and is highly 
applicable to large numbers of samples derived from population-based 
studies.  Importantly, it also removes the need for extensive sample 
manipulation that could modify platelet phenotype and/or bias towards 











Chapter 4 - Isolation and functional analysis 







The platelet population as a whole is considered to be a heterogeneous 
mix of various sub-populations each with distinct biological capabilities 98. 
Reticulated platelets, that is platelets rich in mRNA from their progenitor 
megakaryocytes 159, are currently attracting great research interest for 
two particular reasons.  Firstly, because analysis of the mRNA within 
reticulated platelets may provide a window into the processes of platelet 
formation and the activity of megakaryocytes within the bone marrow.  
Secondly, because reticulated platelets may be particularly reactive and 
so key players in the development of thrombosis. 
 
In normal physiological conditions human platelets survive within the 
circulation for some 7-10 days following their release from the bone 
marrow.  Despite lacking a nucleus, these platelets contain a host of 
mRNAs, most of which are derived from the parent megakaryocyte. The 
residual mRNA from the megakaryocytes largely disappears within the 
first day or two of platelets entering the circulation meaning that the vast 
majority of this residual mRNA appears to reside within a small population 
of recently formed platelets, known as reticulated platelets. As can be 
reasoned from the difference between the survival of progenitor mRNA 
and the circulating life span of platelets, these reticulated platelets are 
estimated to account for around 10% of the total platelet population 94.  
 
Functionally, reticulated platelets are often reported to be more reactive 
than non-reticulated platelets, however rigorous in vitro and ex vivo 
evidence is lacking. Some work has indicated that this population has an 
increased thrombotic potential due to the observation that reticulated 
platelets are more readily recruited into forming thrombi 160. The clinical 
relevance of this population is also pertinent to the study of dual 
antiplatelet therapies where they may account for some of the high on 
treatment platelet reactivity in particular patient groups 96,161. In particular, 
there is evidence linking reticulated platelets to high platelet reactivity and 
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consequent increase in the incidence of acute coronary syndromes and 
myocardial infarction 95,97,162. Other diseases associated with increased 
platelet turnover or an increased reticulated platelet count include 
diabetes 163, kidney dysfunction 100 and sepsis 164. Thus this population of 
platelets may provide an interesting target for novel therapeutics.  This 
chapter therefore aims to establish a protocol for the isolation of 
reticulated platelets from PRP to subsequently investigate the reactivity of 





4.2 Methodology  
 
4.2.1 Blood collection and preparation of PRP 
 
Blood was obtained from healthy volunteers and PRP/PPP prepared as 
outlined previously in section 3.2.1 and 3.2.2.    
 
4.2.2 Thiazole orange staining of platelets  
 
Thiazole orange is an intracellular nucleic acid binding fluorescent dye 
(excitation wavelength of 510 nm and emission wavelength of 530 nm) 
and was used to determine the presence of RNA within platelets as an 
indicator of reticulation status. Thiazole orange was made to a 
concentration of 2 mg/mL in 100% methanol and then diluted to a 
concentration of 20 µg/mL in saline. 10 µL of thiazole orange (20 µg/mL) 
was added to 1 mL PRP and incubated at room temperature for 30 min.  
 
4.2.3 Light transmission aggregometry (LTA) agonist stimulation of 
thiazole orange stained PRP  
 
225 µL of thiazole orange stained PRP was added to add to each test 
cuvette and stimulated with 25 µL of agonist as described in section 3.2.6 
to achieve final concentrations of arachidonic acid 1 mM, ADP 20 µM, 
collagen 10 µg/mL or TRAP-6 25 µM.  
 
4.2.4 Flow cytometric sorting of reticulated, intermediate and 
non-reticulated platelets from PRP   
 
Thiazole orange stained PRP was stirred for 5 min in the 
PAP8E-aggregometer prior to cell sorting. 1 mL of this was then added to 
7 mL of HEPES-modified Tyrode's buffer as previously detailed, 
supplemented with glucose (0.1%), bovine serum albumin (0.35%), 
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apyrase (0.04 U/ml), PGE1 (2 µM) and CaCl2 (2 mM) for activation 
experiments and saline supplemented with apyrase (0.04 U/ml), 
PGE1 (2 µM) and IBMX (0.5 mM) for qRT-PCR experiments. Platelets 
were sorted using a BD FACSAria Fusion based on gating according to 
thiazole-orange fluorescence. The top 10% of thiazole orange bright cells 
were gated as reticulated platelets, the middle 50% thiazole orange bright 
cells were gated as intermediate platelets and the bottom 30% of thiazole 
orange bright cells were gated as non-reticulated platelets.  
 
4.2.5 qRT-PCR analysis for mRNA of genes of interest present within 
the three thiazole orange sorted populations 
 
RNA was extracted using the RNeasy minikit as outlined in section 3.2.9 
and cDNA synthesised using the SuperScript III synthesis system as 
outlined in section 3.2.10. Target genes were selected based on their 
specificity to platelets (ITGA2B Hs01116228_m1, PF4 Hs00427220_g1, 
TUBB1 Hs00258236_m1) or by their known involvement to pathways 
important to platelet function (ADCY3 Hs01086502_m1, GP6 
Hs00212574_m1, GUCY1A3 Hs01015574_m1, P2RY1 Hs00704965_s1, 
P2RY12 Hs01881698, PEAR1 Hs01378394, PLA2G4A Hs00233352_m1, 
PTGIR Hs00168765, PTGS1 Hs003777726_m1, TBXAS1 Hs01022706). 
Taqman probes were used for all targets.  
 
4.2.6 Flow cytometric assessment of platelet activation 
 
Flow cytometry was used to quantify either the number of CD26P PE 
(1:80 dilution) positive events per 100,000 CD61 APC (1:160) positive 
events or to obtain mean fluorescence intensity values for the total 
CD62P positive events as indicators of platelet activation as described in 
detail in section 3.2.9. Data was acquired on a FACSCalibur flow 
cytometer using CellQuest software. 
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4.2.7 ATP release from agonist stimulated reticulated, intermediate 
and non-reticulated platelets 
 
ATP release from platelet dense granules can be used as an indication of 
platelet activation. 2.5 million reticulated, intermediate and non-reticulated 
platelets were sorted as described in 4.2.4. The cells were pelleted at 
1000 x g for 10 min with the addition of PGI2 2 µM and subsequently 
resuspended in 45 µL of modified Tyrode’s-HEPES buffer supplemented 
with CaCl2 (0.1M) and fibrinogen (1 mg/mL). The platelets (2.5 million in 
45 uL) were then placed into wells of a 96-well white, half area, flat 
bottom microtitre plate and stimulated with TRAP-6 (25 µM) by shaking 
on a plate shaker for 2 min at 1200 rpm. 25 uL of Chronolume 
luciferin-luciferase system reagent was then added to each well and 
shaken slowly for 2 min at 350 rpm. ATP release was subsequently 
determined by assessing the luminescence emitted by each well using a 
Tecan Infinite® M200 plate reader and comparing to standard ATP 
concentrations. A summary of the light emitting reaction is outlined below.  
 
 
Luciferin + ATP → Luciferyl Adenylate + Inorganic phosphate [PPi] 
Luciferyl Adenylate + O2 → Oxyluciferin + AMP + LIGHT 
 
 
4.2.8 Liquid chromatography tandem mass spectrometry 
(LC-MS/MS) analysis of agonist stimulated lipid release from 
reticulated, intermediate and non-reticulated platelets  
 
10 million reticulated, intermediate and non-reticulated platelets were 
sorted as described in 4.2.4. The cells were pelleted at 1000 x g for 10 
min with the addition of PGI2 2 µM and subsequently resuspened in 
900 µL of modified Tyrode’s-HEPES buffer supplemented with 
CaCl2 (0.1M) and fibrinogen (1 mg/mL). Each cell suspension was then 
divided into three LTA cuvettes and stimulated with PBS, TRAP-6 amide 
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(25 µM) or collagen (30 mg/mL) in a PAP8E aggregometer for 30 min at 
37°C whilst being continually stirred. 30 µL of diclofenac/heparin solution 
(31.8 mg diclofenac sodium salt, 8.8 mL phosphate buffered solution, 
200 µL heparin) was then added to each cuvette to stop the reaction. The 
contents of the cuvettes were transferred into 1.5 mL eppendorf tubes 
and centrifuged at 1000 x g. Supernatants (200 µL) were removed and 
stored at -80°C until required.  
 
Samples were sent to Matthew Edin at The National Institute of 
Environmental Health Science, North Carolina, USA for liquid 
chromatography tandem mass spectrometry analysis. Samples were 
spiked with 3ng each PGE2-d4, d8-11,12-DHET, d8-11,12-EET as 
internal standards, mixed with equal volume of 0.1% acetic acid in 5% 
methanol, and extracted by liquid:liquid extraction with 3 ml ethyl acetate. 
Ethyl acetate was transferred into glass tubes containing 6 µL of 30% 
glycerol in methanol. Ethyl acetate was evaporated by vacuum 
centrifugation, and the dried tubes covered with argon and stored at          
-80°C until analysis. Samples were reconstituted in 50 µL of 30% ethanol. 
Samples were analyzed in duplicate 10 µL injections. Online liquid 
chromatography of extracted samples was performed with an Agilent 
1200 Series capillary HPLC Separations were achieved using a Halo C18 
column (2.7 mm, 10062.1 mm) which was held at 50°C. Mobile phase A 
was 85:15:0.1 water:acetonitrile:acetic acid. Mobile phase B was 
70:30:0.1 acetonitrile:methanol:acetic acid. Flow rate was 400 µL /min. 
Gradient elution was used; mobile phase percentage B and flow rate 
were varied as follows: 20% B at 0 min, ramp from 0 to 5 min to 40% B, 
ramp from 5 to 7 min to 55% B, ramp from 7 to 13 min to 64% B. From 13 
to 19 min the column was flushed with 100% B at a flow rate of 550 µL 
/min. Mass spectroscopy was performed on an MDS Sciex API 3000 
equipped with a TurboIonSpray source. Turbo desolvation gas was 
heated to 425°C at a flow rate of 6 L/min. Negative ion electrospray 
ionization tandem mass spectrometry with multiple reaction monitoring 
was used for detection. Quantification was done using Analyst 1.5.1 
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software comparing relative response ratios for each analyte/internal 
standard to standard curves for each analyte. 
 
4.2.9 Flow cytometric assessment of the ability of the sorted 
platelets to aggregate 
 
2.5 million thiazole orange stained reticulated or non-reticulated platelets 
were sorted from PRP prepared from three separate healthy volunteers 
on three separate days. Sorted platelet samples were then stained with 
CD61 FITC (reticulated) or CD61 APC (non-reticulated, both 
eBioscience, UK) and centrifuged at 1000 x g for 10 min with the addition 
of PGI2 2 µM to produce platelet pellets.  Subsequently pellets were 
re-suspended in filtered modified Tyrode’s-HEPES buffer and recombined 
in equal proportions.  Aggregation was stimulated with TRAP-6 amide 
(25 µM) in a half-area 96-well plate as previously described and samples 
subsequently fixed with 1% formalin. Flow cytometric imaging 
(Imagestream X Mark II) was then used to analyse non-aggregated single 
platelets and formed aggregates (283±49 aggregates per sample). 
Images were individually assessed and scored by three separate 
individuals using IDEAS software (Amnis, Seattle, WA).  
 
4.2.10 Flow cytometric assessment of reticulated platelet loss from 
the single platelet population following agonist stimulation 
 
225 µL of thiazole orange stained PRP was added to add to each test 
cuvette and stimulated with 25 µL of agonist as described in section 3.2.6 
to achieve final concentrations of arachidonic acid 1 mM, ADP 20 µM, 
collagen 10 mg/mL or TRAP-6 2.5 µM as above. Samples were 
stimulated until 40% aggregation had been reached. Flow cytometry was 
then used to select for the reticulated platelet population within PRP by 
gating for the top 10% of thiazole orange bright cells and to then assess 
the loss of this single platelet population following agonist stimulation and 
the consequent formation of platelet aggregates. Imaging flow cytometry 
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using the Imagestream X Mark II cytometer was used on the same 
samples to visualise the formation of aggregates.   
 
4.2.11 Statistical analysis 
 
All statistical analyses were conducted used GraphPad Prism v6 
(GraphPad Software, Inc, USA) and are described in each results 




4.3.1 Assessing the impact of thiazole orange staining on platelet 
function 
 
LTA as described in 4.2.3 was used to assess the function of thiazole 
stained platelets. For each agonist used (A; arachidonic acid, B; ADP, C; 
collagen, D; TRAP-6) there was no significant difference in the 
percentage aggregation measured between thiazole orange 
(TO; 20 µg/mL) treated and vehicle (1% methanol in saline) treated PRP 






Figure 4.1 LTA data comparing percentage aggregation of PRP 
treated with either thiazole orange or vehicle 
 
LTA aggregation data presented as final percentage aggregation. Results 
displayed as individual data points with mean ± SEM (n=8). *p<0.05 by 



















































































4.3.2 Assessing the impact of thiazole orange staining on Ct values 
obtained by qRT-PCR 
 
Thiazole orange is a non-specific nucleic acid stain that freely permeates 
live cell membranes. 2 mL of PRP was stained with 20 µL of 20 µg/mL 
thiazole orange before being mixed in the PAP8E-aggregometer for 5 min 
to decrease non-specific binding of thiazole orange to free nucleotides 
within platelet granules. qRT-PCR was then utilised to obtain average Ct 
values as an indication of RNA content for thiazole orange stained PRP 
versus vehicle-treated PRP. Figure 4.2A shows there was significant 
difference between vehicle and thiazole orange stained PRP at 30 and 
60 min for TUBB1. For all other TUBB1 time points and all time points for 
ITGA2B and PF4 there was no significant difference. For all proceeding 
thiazole orange-based experiments the time point of 180 minutes was 
selected based on the stability of the Ct value, as demonstrated in this 
figure. Consultation with the flow cytometry facility suggested a sorting 
time of 180 minutes to obtain sufficient platelets for downstream flow 





Figure 4.2 The effect of thiazole orange staining and time on the 
mean expression levels of three abundant platelet genes  
 
qRT-PCR analysis comparing the mean Ct value for three genes which 
are abundant in platelets; ITGA2B (A), PF4 (B) and TUBB1 (C) in RNA 
samples extracted from 1 mL PRP at four time points. Each gene was run 
in triplicate. Results displayed as mean ± SEM (n=3). A one-way ANOVA 
with a multiple comparisons test comparing each mean to the control 
mean (PRP incubated with 1% methanol in PBS for 30 min and 



























































4.3.3 Isolation of reticulated platelets based on thiazole orange 
intensity using flow cytometry  
 
Flow cytometric cell sorting of thiazole orange stained PRP was achieved 
using the FACSAria Fusion cell sorter. PRP was incubated with 20 µg/mL 
thiazole orange at room temperature for 30 min before being diluted 1 in 
8 with a modified HEPES buffer plus the platelet inhibitors PGE1 and 
apyrase as described in the methods section 4.2.4. The sample was then 
taken to the cell sorter and based on side scatter and thiazole orange 
fluorescence intensity three platelet subpopulations were defined as 
follows; reticulated platelets gated as the top 10% of thiazole orange 
bright cells, intermediate platelets as the middle 50% of thiazole orange 
bright cells and non-reticulated platelets as the bottom 30% of thiazole 
orange bright cells. Figure 4.3 shows the gating parameters for selection 







Figure 4.3 Isolation of reticulated platelet subpopulation  
 
Flow cytometry dot–plot of thiazole orange staining of entire platelet rich 
plasma sample, and gating of three subpopulations for cell sorting (A). 
B shows the subsequent three populations (red, non-reticulated; 
blue, intermediate; green, reticulated) expressed as a thiazole orange 
intensity histogram.  
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4.3.4 Comparing the mRNA content of the isolated reticulated, 
intermediate and non-reticulated platelet subpopulations 
 
Reticulated platelets are thought to have acquired their name due to the 
abundance of RNA and ribosomes within their cytoplasm however robust 
evidence is lacking. Figure 4.4 shows qRT-PCR data obtained from RNA 
samples extracted from the three platelet sub-populations cell sorted on 
the basis of thiazole orange staining. Reticulated platelets have 
significantly lower mean Ct values for three abundant platelet genes, 
equating to a higher concentration of mRNA for each gene than either the 
non-reticulated or intermediate sub-populations. All genes were tested in 
triplicate. 
 
qRT-PCR analysis was also carried out for functional genes of interest to 
see if mRNA expression levels in the subpopulations displayed the same 
characteristic as for the abundant platelet genes. All functional genes, 
excluding PLA2G4A, showed a significant reduction in mean Ct value in 
the reticulated sub-population compared to both the intermediate and 







Figure 4.4 Comparison of detection of selected mRNAs for the three 
isolated platelet subpopulations 
 
qRT-PCR analysis comparing the mean Ct values of the genes ITGA2B, 
PF4 and TUBB1 in RNA samples isolated from 10,000,000 
non-reticulated, intermediate and reticulated platelets sorted from PRP 
samples using the FACSAria flow cytometer. Results displayed as 
individual data points with mean ± SEM (n=3). *p<0.05 by one-way 

































Figure 4.5 Comparison of detection of selected mRNAs for the three 
isolated platelet subpopulations – functional genes of interest  
 
qRT-PCR analysis comparing the mean Ct values of the genes ADCY3, 
GP6, GUCY1A3, P2RY12, P2RY1, PEAR1, PLA2G4A, PTGIR, PTGS1 
and TBXAS1 in RNA samples isolated from 10,000,000 non-reticulated, 
intermediate and reticulated platelets sorted from PRP samples using the 
FACSAria flow cytometer. Results displayed as individual data points with 
mean ± SEM (n=3). *p<0.05 by one-way ANOVA with Tukeys multiple 









































































4.3.5 Assessing platelet activation in the isolated reticulated, 
intermediate and non-reticulated platelet subpopulations 
 
Platelet surface P-selectin (CD62P) expression in response to either 
TRAP-6 2.5 µM or 25 µM was measured using flow cytometry. 10 million 
reticulated, intermediate and non-reticulated platelets were sorted based 
on thiazole staining intensity as described in section 4.2.4. The cells were 
then pelleted and resuspended in HEPES-modified Tyrode's buffer as 
previously detailed, supplemented with glucose (0.1%), bovine serum 
albumin (0.35%), CaCl2 (2 mM) and fibrinogen (1 mg/mL) before being 
stimulated with either TRAP-6 or vehicle for 20 min at 25°C. Samples 
were incubated with CD61-APC as the platelet identifier and with 
CD62P-PE for P-selectin expression. 
 
Figure 4.6 shows that reticulated platelets have a significantly higher fold 
increase in surface P-selectin expression than non-reticulated when 








Figure 4.6 Relative P-selectin (CD62P) expression following 
incubation with TRAP-6 for the reticulated, intermediate and 
non-reticulated platelet populations 
 
Flow cytometric analysis comparing the relative change in CD62P 
expression in response to (A) 2.5 µM or (B) 25 µM TRAP-6 amide 
stimulation of reticulated, intermediate and non-reticulated platelets 
(which were set at the hypothetical value of one). Results displayed as 
mean ± SEM. A one-way ANOVA was used to determine significance 


















































































4.3.6 Comparison of ATP release from the isolated reticulated, 
intermediate and non-reticulated platelet subpopulations following 
incubation with TRAP-6  
 
2.5 million reticulated, intermediate and non-reticulated platelets were 
sorted based on thiazole staining intensity as described in section 4.2.4 
and stimulated with TRAP-6 25 µM in the wells of a white half area flat 
bottom 96 well plate before a luminescence assay was used to determine 
ATP release as described in section 4.2.7. Compared to non-reticulated 
platelets intermediate platelets demonstrated a 1.8±0.4 fold increase in 
ATP release and reticulated platelets a 3.0±0.4 fold increase in ATP 
release (Figure 4.8).  
 
The production of an ATP standard curve (Figure 4.7) enabled 
quantification of the ATP release for each group. There was no significant 
effect of the time taken between stimulating the platelets and reading the 
plate on luminescence value. Using this curve it was determined that the 
average ATP release (based on raw luminescence values) from the 
non-reticulated samples was 10.17 pmol, from the intermediate samples 
was 15.02 pmol and from the reticulated samples was 28.15 pmol as 













Figure 4.7 ATP standard curves for multiple time points post agonist 
stimulation 
 
Luminescence readings for 24 serial 1 in 2 dilutions of ATP for six time 
points (0 min black, 1.5 min blue, 3 min pink, 4.5 min green, 6 min 
orange) post agonist stimulation. Results displayed as mean ± SEM. A 
two-way ANOVA with Tukey’s multiple comparisons test was used to 
determine significance (p<0.05; n=3).    
ATP Standard Curve






























Figure 4.8 Relative ATP release from the reticulated, intermediate 
and non-reticulated platelet populations in response to TRAP-6 
 
Luminescence based analysis comparing the relative fold change in ATP 
release in response to TRAP-6 (25 µM) between reticulated and 
intermediate platelets compared to non-reticulated platelets, which were 
set at the hypothetical value of one. Results displayed as mean ± SEM. A 
one-way ANOVA with Holm-Sidak multiple comparisons test was used to 



















































Table 4.1 Average ATP release (pmol) for each platelet 
sub-population 
 
Table summarising the quantification of mean ± SEM ATP release (pmol) 
from each of the three thiazole orange sorted platelet sub-populations 
using data from the ATP standard curve (Figure 4.7) and raw 










4.3.7 Comparison of eicosanoid production by isolated reticulated, 
intermediate and non-reticulated platelet subpopulations in 
response to collagen 
 
10 million reticulated, intermediate and non-reticulated platelets were 
isolated (section 4.2.4) and incubated with either vehicle or collagen 
(30 µg/mL) for 30 min at 37°C. Supernatants from these samples were 
analysed by LC-MS/MS as described in section 4.3.8. Data in Figure 4.9 
shows that there was no significant difference in the levels of 
thromboxane B2 (Figure 4.9 A), prostaglandin D2 (Figure 4.9 C), 
prostaglandin E2 (Figure 4.9 C), 11-HETE (11-hydroxy-5,8,12,14-
eicosatetraenoic acid) (Figure 4.9 D) 12-HETE (12-hydroxy-5,8,12,14-
eicosatetraenoic acid) (Figure 4.9 E) or 15-HETE (15-hydroxy-5,8,12,14-
eicosatetraenoic acid) (Figure 4.9 F) measured in the supernatants from 





Figure 4.9 LC-MS/MS analysis of selected arachidonic acid 
metabolites in supernatants of reticulated, intermediate and 
non-reticulated platelet subpopulations incubated with collagen or 
vehicle 
 
Data presented as individual data points with mean ± SEM. Significance 









































































































































































































































































































































































4.3.8 Comparing the ability of reticulated and non-reticulated 
platelets to form aggregates 
 
Stimulation of equally mixed populations of platelets (54±2% reticulated 
vs. 45±2% non-reticulated, p>0.05) with TRAP-6 led to the formation of 
platelet aggregates (Figure 4.10). Of all formed aggregates, reticulated 
platelets were present in 95±2% and non-reticulated platelets in 42±6% 
(Figure 4.11 A).  Further analysis demonstrated that 57±6% of all 
aggregates were composed exclusively of reticulated platelets, whereas 
only 4±2% were composed exclusively of non-reticulated platelets. The 
remaining 39±7% of aggregates were formed from combinations of the 








Figure 4.10 Relative reactivity of reticulated and non-reticulated 
platelets during aggregation   
 
Flow cytometric sorted reticulated (green, CD61-FITC) and 
non-reticulated (red, CD61-APC) platelets were recombined in equal 
measures before stimulation with TRAP-6 (25 µM). Representative dot 
plots from flow cytometric imaging (incorporating x60 magnification) 
analysis of samples before (left) and after (right) stimulation 















Figure 4.11 Relative reactivity of reticulated and non-reticulated 
platelets during aggregation – aggregate composition    
 
Images of aggregates formed (Figure 4.10) were scored for the (A) total 
presence and (B) composition with respect to each sub-population and 
revealed the involvement of reticulated platelets, either alone or in 
combination with non-reticulated platelets, in almost all formed 
aggregates. Scale bars represent 7 µm.  Data reported as mean ± SEM 




4.3.9 Determining the proportional recruitment of reticulated and 
non-reticulated platelets to aggregate formation  
 
PRP samples from healthy volunteers were stained with thiazole orange 
as described in section 4.4.2 and stimulated with arachidonic acid 1 mM 
(Figure 4.13 A), ADP 20 µM (Figure 4.13 B), collagen 1 µg/mL 
(Figure 4.13 C) or TRAP-6 2.5 µM (Figure 4.13 D) until 40% aggregation 
had been achieved, samples therefore contained a mix of 
non-aggregated single platelets and aggregates. The samples were then 
incubated with CD61 APC to identify platelets and a flow cytometric 
assay was used to track the change in the proportion of reticulated 
platelets within the single platelet population in vehicle compared to 
agonist stimulated samples. Gating strategies for the identification of the 
reticulated platelet population are outlined in Figure 4.12. Data presented 
in Figure 4.13 shows a significant decrease in the percentage of 
reticulated platelets in the single platelet population post agonist 
stimulation compared to vehicle for all four agonists used. Reticulated 
platelets are therefore recruited into forming aggregates in a manner that 
is disproportional to the platelet population as a whole. In addition the 
formed aggregates were examined using imaging flow cytometry 
(Figure 4.14) to confirm the presence of reticulated platelets in the 













Figure 4.12 Gating strategies for the identification of reticulated 
platelets in the single platelet population  
 
Representative flow cytometric histograms showing the gates used to 
identify single platelets based on CD61 expression in PRP treated with 
either vehicle (A) or TRAP-6 25 µM (B). Reticulated platelets were 
defined as the top 10% of thiazole orange bright platelet events in vehicle 
samples (C). The percentage change in this population was measured in 








Figure 4.13 Flow cytometric analysis of reticulated and 
non-reticulated platelet recruitment into forming aggregates  
 
The proportion of reticulated platelets among the non-aggregated single 
platelet population was assessed by flow cytometry in PRP samples 
stimulated with arachidonic acid 1 mM (A), ADP 20 µM (B), collagen 
1   µg/mL (C) or TRAP-6 2.5 µM (D). Results displayed as individual data 
points with overlaid mean ± SEM (n=6) and significance determined using 








































































































































Figure 4.14 Representative Imagestream analysis of forming 
aggregates 
 
Representative flow cytometric images (Imagestream X Mark II cytometer) 
of samples analysed in Figure 4.10 showing non-reticulated single 
platelets (A) and reticulated (mRNA stain green) single platelets (red) (B), 
as well as aggregates formed in response to ADP 20 µM (C).   
Non-reticulated single platelet 
Reticulated single platelet 





















Reticulated platelets are currently of much research interest. Their 
precise and accurate study is dependent upon obtaining defined platelet 
populations with preserved function.  
 
Building upon the optimal platelet isolation technique outline in the 
previous chapter a protocol was developed, based on thiazole orange 
staining, to extract reticulated platelets from PRP (Figure 4.3) and 
subsequently to investigate both their mRNA content and function. The 
use of thiazole orange to identify platelets containing elevated levels of 
mRNA has previously been questioned on the basis that larger platelets 
may uptake more dye and that this may skew the analysis 165. For the first 
time through careful separation this series of experiments confirms that 
platelets with stronger thiazole orange staining contain significantly 
greater amounts of platelet associated mRNA, for both abundant platelet 
genes ITGA2B, PF4 and TUBB1 (Figure 4.4) and for genes important to 
platelet function (Figure 4.5). Furthermore this staining was found to have 
no effect on platelet function as measured using LTA (Figure 4.1) or on 
the stability of measured Ct values indicating no loss of mRNA over time 
(Figure 4.2). Although megakaryocyte-derived platelet-specific mRNA 
declines within platelets as they age it is now understood that platelets 
take up a wide variety of RNAs released into the circulation by other cell 
types 82. As such, total RNA levels within the platelet may be unaffected. 
My targeted approach for the study of platelet specific mRNA eliminates 
this potentially confounding observation. 
 
In terms of platelet function, through my approach of platelet staining and 
testing, I was able to demonstrate definitively that platelets containing 
higher amounts of mRNA (i.e. the most newly formed, reticulated, 
platelets) have an exaggerated response to TRAP-6 as determined by 
the surface expression of CD62P and by ATP release. Indeed the 
reticulated platelet population was shown to express a 2.6 fold increase in 
surface CD62P expression (Figure 4.6) and to release 2.8 times more 
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ATP when stimulated compared to the non-reticulated population 
(Figure 4.8). Trends in the LC-MS/MS data also support idea that the 
reticulated platelet population is more reactive showing that this 
population may release greater amounts of functionally relevant 
eicosanoids in response to agonist stimulation. It would be interesting to 
investigate this further to determine whether the increased eicosanoid 
release can be attributed to an increased ability to metabolise arachidonic 
acid through the enzymatic pathways as outlined in subsequent chapters. 
It should be note this idea is based on trends in the data that did not 
reach statistical significance (Figure 4.9). 
 
The reticulated platelets also showed elevated reactivity during aggregate 
formation. This was demonstrated by individually staining the reticulated 
and non-reticulated platelets with different fluorophores, before 
recombining the populations in equal proportions, and using flow 
cytometric imaging (Figure 4.10) to demonstrate that reticulated platelets 
were involved in around 95% of all aggregates compared to 42% for 
non-reticulated platelets. Furthermore, 57% of aggregates were formed 
entirely from reticulated platelets (Figure 4.11).   
 
In the more physiologically relevant environment of PRP, reticulated 
platelets were once again identified based on thiazole orange staining 
intensity and analysed in situ (Figure 4.12). Just as in the isolated 
samples, reticulated platelets were recruited in a disproportional manner 
from the non-stimulated single platelet population into aggregates 
following exposure to platelet agonists (Figure 4.13). Flow cytometric 
imaging analysis further showed that the reticulated platelets were 
present at the centre of aggregates and were therefore most likely 
recruited first in preference to the non-reticulated platelets.  
 
Despite the fact that reticulated platelets normally comprise only 10% of 
the total platelet count, the increased reactivity demonstrated here 
provides evidence that reticulated platelets can be drivers of the 
thrombotic response. This supports clinical observations associating 
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increased platelet turnover or immature platelet counts with high platelet 
reactivity 166,167 and increased incidence of acute coronary syndromes in 
patients with higher reticulated platelet counts or elevated platelet 
turnover 95. The mechanisms underlying this increased reactivity require 
further research for which the methodology presented could be 
particularly helpful.  
 
To summarise, reticulated platelets are of great current research interest 
owing to fact that they contain an abundance of platelet-specific mRNA 
and increased reactivity.  The experiments described here present an 
optimised approach for reticulated platelet isolation that preserves these 
properties to permit both genetic and functional downstream analysis.  
Moreover, using this approach it was established that reticulation status is 
directly linked to an increased expression of platelet-specific mRNA and, 













Chapter 5 - Functional and RNA sequencing 
analysis of platelets obtained from a 
cytosolic phospholipase A2α (cPLA2α) 







A patient with a homozygous 4 base pair deletion within the PLA2G4A 
gene resulting in the loss of the C-terminal region of the group IV A 
cytosolic phospholipase A2 (cPLA2α) protein 168 was identified at the 
department of clinical immunology at The Royal London Hospital 
(Barts Health NHS Trust of London).   
 
As discussed below, cPLA2α enzyme is central to the production of a 
wide range of bioactive eicosanoids and phenotypically the patient 
presented with an extensive life-long history of severe peptic and 
intestinal ulceration, small intestinal strictures and fibrosis and duodenal 
stenosis. Collectively these features suggested a diagnosis of cryptogenic 
multifocal ulcerating stenosis enteritis (CMUSE) 169. The gastrointestinal 
lesions of patients with this rare condition often resemble those 
associated with the chronic use of non-steroidal anti-inflammatory drugs 
(NSAIDS) such as aspirin 170. This patient was the first known case of 
CMUSE linked to a homozygotic mutation within PLA2G4A gene that 
encodes for the cPLA2α enzyme leading to its inactivation. 
 
cPLA2α is one of 19 identified PLA2 isoforms that are classified into three 
families (cytosolic calcium dependent cPLA2; cytosolic calcium 
independent; iPLA2 and secretory; sPLA2) based on enzymatic function, 
biochemical structure and cellular distribution. cPLA2α requires 
submicromolar- concentrations of Ca2+ for its activation and translocation 
from the cytoplasm to the membrane of the cells in which it is present 171–
173. Together these enzymes have a critical role in the production of 
bioactive lipids through the hydrolysis of arachidonic acid from the cell 
membrane 174.  
 
Arachidonic acid is the precursor to many other lipid mediators called 
eicosanoids. Eicosanoid formation from arachidonic acid requires the 
action of three enzymatic pathways, the cyclooxygenase (COX) -1 and -2 
pathway, the 5-, 12- and 15-lipoxygenase (LOX) pathway and the 
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cytochrome P450 epoxygenase ω-hydroxylase pathway 171,175 (Figure 
5.1).  
 
Through the action of COX-1 and 12-LOX platelets produce eicosanoids 
that regulate platelet, WBC and vascular function 43. Through the activity 
of COX-1 platelets produce prostaglandin G2 (PGG2) that is reduced to 
prostaglandin H2 (PGH2). PGH2 is further converted into prostaglandin D2 
(PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostacyclin 
(PGI2) and thromboxane A2 (TXA2) via the action of specific synthase 
enzymes 176,177. Through the action of 12-LOX platelets produce 
12-hydroxyeicosatetraenoic acid (12(S)-HETE) 178.   
 
Previous studies have shown that the loss of cPLA2α activity significantly 
alters the ability of platelets both to respond to agonist stimulation and to 
synthesise various arachidonic acid derived eicosanoids essential to 
platelet function 179,180. Figure 5.2 highlights the platelet specific 
production of eicosanoids and their biological functions.    
 
This chapter aims to test the reactivity of platelets from the cPLA2α 
mutated patient by comparing them to data obtained from healthy control 
samples using multiple platelet function testing assays. In addition RNA 
sequencing (RNA-Seq) analysis will be carried out in order to determine 







Figure 5.1 General scheme of arachidonic acid derived eicosanoid 
products  
 
Figure showing the conversion of arachidonic acid into its bioactive 
eicosanoid products via the lipoxygenase (LOX), cyclooxygenase (COX) 
and cytochrome P450 pathways. PG = prostaglandin, TX = thromboxane, 

































Figure 5.2 Arachidonic acid derived eicosanoid products – platelet 
specific 
 
Figure showing the conversion of arachidonic acid into its bioactive 
eicosanoid products via the 12-lipoxygenase (12-LOX) and 
cyclooxygenase-1 (COX-1) specific to platelets. Eicosanoid effects on 
platelet function are shown next to the abbreviation. PG = prostaglandin, 






















5.2 Methodology  
 
5.2.1 Blood collection and preparation of PRP 
 
Blood was obtained from healthy volunteers or the patient of interest and 
PRP/PPP prepared as outlined previously in section 3.2.1 and 3.2.2. 
Written informed consent was obtained from the patient. This study was 
approved by the South East NHS Research Ethics Committee and was 
performed according to the Declaration of Helsinki Principles. At the time 
of sampling a proton pump inhibitor was the only medication the patient 
was prescribed.  
 
5.2.2 Light transmission aggregometry (LTA) 
 
225 µL of PRP was added to each cuvette that was then placed in one of 
eight channels in a Bio/Data PAP-8E turbidometric aggregometer and 
stimulated with 25 µL of agonist as described in section 3.2.6. Agonists 
and their final concentrations used were as follows; ADP 10 µM, 
epinephrine 10 µM, TRAP-6 25 µM, U46619 3 µM, arachidonic acid 
1 mM, ristocetin 1.5 mg/mL and collagen 1 µg/mL or 3 µg/mL.  
 
5.2.3 Optimul plate assay 
 
Optimul plates were prepared according to section 3.2.7. For their use, 
40 uL of PRP or PPP was added to the appropriate wells and plates 
shaken on a Bioshake plate shaker at 1200 rpm, for 5 min at 37°C before 
the absorbance was read at 595 nm on a Tecan Sunrise plate reader. 
Agonists used were ADP (0.00540 µM), epinephrine (0.0004-10 µM), 
TRAP-6 amide (0.03-40 µM), U46619 (0.055-40 µM), arachidonic acid 




5.2.4 Luminescence (lumi) aggregometry – ATP release 
 
Lumi-aggregometry measures the release of ATP from platelet dense 
granules as an indication of activation. It is a bioluminescent assay using 
the luciferin-luciferase system. 
 
200 µL of PPP was added to four flat bottom cuvettes and placed in the 
four channels of the lumi-aggregometer to set baselines. The trace line 
was left to settle for 2 min before placing a cuvette containing 200 µL 
PRP into the sample wells. All PPP and PRP cuvettes contained 20 µL 
chrono-lume reagent. Samples were continually stirred and kept at 37°C. 
PRP was left to equilibrate for 2 min before 25 µL of chosen inhibitor was 
added. 1 min later 5 µL of selected agonist was added and the trace was 
left to run for a further 5 min after which 5 µL of 2 µM ATP standard was 
added. Once the trace had settled the experiment was ended. 
Aggregation and luminescence traces were recorded and analysed using 
Chart v4.2. 
 
The calculation used to determine maximum ATP release is as follows 
and its derivation is explained in Figure 5.3:  
 








Figure 5.3 Example lumi aggregometry trace 
 
Figure showing an example luminescence trace obtained by lumi 
aggregometry. The trace is labelled to show how the components of the 










5.2.5 Platelet surface P-selectin expression – whole blood 
 
A flow cytometric assay was used to assess platelet surface P-selectin 
(CD62P) expression as an indicator of platelet activation in response to 
agonist stimulation 181. 45 µL of whole blood was added to wells of a 
gelatin coated half area plate containing 5 µL of agonist or vehicle to 
achieve final concentrations of ADP 40 µM, U46619 0.5 µM, or a 
combination of both. The plate was then shaken at 1200 rpm for 5 min. 
160 µL of ACD (2.2 g sodium citrate dehydrate, 0.7 g citric acid, 
2.4 g dextrose, 100 mL dH2O) was then added to each well to terminate 
reaction and prevent aggregation. 10 µL of the sample was then 
incubated for 30 min in the dark at 4°C with an equal volume of an 
antibody mix containing CD61 APC (1:160) as the platelet identifier and 
CD62P PE (1:80) as the indicator of activation in saline. Samples were 
fixed using 1% formalin in saline. Flow cytometry was then used to 
quantify mean fluorescence intensity values for 100,000 CD61 positive 
events. Data was acquired on a FACSCalibur flow cytometer using 




5.2.6.1 Platelet RNA extraction  
 
RNA was extracted from 25-30 mL of PRP obtained from 100 mL of 
whole blood for each of the six control donors and from three samples 
taken on separate days from the test patient. RNA was extracted using 
the RNeasy minikit as described in full in section 3.2.9.   
 
5.2.6.2 Sample quality control 
 
RNA samples were assessed for quantity and integrity using the 
NanoDrop 8000 spectrophotometer V2.0 and Agilent 2100 Bioanalyser, 
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respectively. Samples displayed low levels of degradation with RNA 
integrity numbers (RIN) between 6.7 and 8.4. 
 
5.2.6.3 cDNA synthesis 
 
Full-length cDNA molecules were generated from 1ng of total RNA per 
sample using the SMARTer kit for cDNA generation. cDNA quantity was 
measured using the Qubit® 2.0 Fluorometer, and were checked for 
quality using the Agilent 2200 Tapestation. 
 
5.2.6.4 Library generation and RNA-sequencing 
 
Libraries were prepared using the Illumina Nextera XT Sample 
Preparation Kit with an input of 150pg of cDNA per sample. 40 million 
75bp paired-end reads were generated for each library using the Illumina 
NextSeq®500 High-output kit. 
 
5.2.7 Statistical analysis 
 
For the platelet function testing assays statistical analyses were 
conducted used GraphPad Prism v6 and described in each results 
section. For RNA-Seq analyses FastQ data was quality checked using 
MultiQC http://multiqc.info/.  Data was aligned to the human genome 
(build hg19) using TopHatv2 implemented in Illumina’s BaseSpace cloud 
resource using the default parameters 182. BAM files were downloaded 
and differential expression analysis performed using Genome Suite. 
Partek v 6.6 was used for the differential gene expression analysis 
annotating reads with the latest build of the RefSeq database (v83). 
Analysis of variance was used to calculate list of differentially expressed 
genes.  The Benjamini-Hochberg, false discovery rate (FDR) method was 
used to control for multiple texting with values reported with an FDR of 
0.05 and fold change of 2 or greater. 
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5.3 Results  
 
5.3.1 Aggregation of platelets from a cPLA2α mutated patient 
measured using LTA 
 
LTA as described in 5.2.2 was used to assess the function of platelets 
belonging to a patient with a mutation in the cPLA2α gene. PRP was 
stimulated in the aggregometer with arachidonic acid 1mM (Figure 5.4 A), 
ADP 5 µM (B), ADP 20 µM (C), collagen 0.4 µg/mL (D), collagen 4 µg/mL 
(E), collagen 10 µg/mL (F), TRAP-6 25 µM (G) or U46619 10 µM (H). 
There was a significant decrease in aggregation measured between 
control and patient in response to ADP 20 µM, collagen 0.4 µg/mL and 





Figure 5.4 LTA data showing percentage aggregation of platelets 
obtained from a cPLA2α-mutated patient compared to healthy 
controls  
 
LTA aggregation data presented as final percentage aggregation. Results 
displayed as mean ± SEM. Two samples were obtained from the test 
patient on two separate days (n=12 for controls, *p<0.05 by unpaired 
































































































































































5.3.2 Aggregation of platelets from a cPLA2α mutated patient 
measured using the Optimul assay  
 
Platelet aggregation was investigated using the Optimul plate assay 
enabling the use of multiple agonists across a concentration range. 
Agonists used were arachidonic acid (Figure 5.5 A), ADP (B), collagen 
(C), epinephrine (D), ristocetin (E), TRAP-6 (F) and U46619 (G). Data in 
Figure 5.3 show that there was a significant decrease in aggregation 
observed for the patient sample compared to control samples for the 





Figure 5.5 Optimul plate data showing percentage aggregation of 
platelets obtained from a cPLA2α-mutated patient compared to 
healthy controls 
  
Optimul plate platelet aggregation data presented as percentage 
aggregation form PRP samples obtained from a cPLA2α mutated patient 
and 20 healthy controls. Results displayed as mean ± SEM. Significance 
was assessed using a two-way ANOVA (p=<0.05).  	




































































































































Table 5.1 Optimul data log EC50 values and 95% confidence 
intervals obtained from a cPLA2α-mutated patient compared to 
healthy control 
 
Log EC50 values and 95% confidence intervals for the non-linear 
regression curves fitted to the Optimul data comparing percentage 
aggregation of PRP samples obtained from a cPLA2α mutated patient and 











Arachidonic	acid -3.37 -3.448 to -3.282 -3.32 -3.319 to -3.318
ADP -5.34 -5.565 to -5.124 -4.74 -5.453 to -4.029
Collagen -6.75 -7.234 to -6.274 -5.03 Not	calculated
Epinephrine -6.48 -6.603 to -6.358 -6.39 -6.957 to -5.813
Rsitocetin -3.03 -3.102 to -2.953 -2.92 -2.974 to -2.857
TRAP-6 -5.55 -5.718 to -5.374 -5.31 -5.425 to -5.193
U46619 -6.79 -6.940 to -6.646 -6.52 -6.651 to -6.389
 148 
5.3.3 Activation of platelets from a cPLA2α mutated patient - ATP 
release 
 
PRP obtained from a cPLA2α mutated patient was stimulated with 
arachidonic acid 1 mM (Figure 5.6 A), ADP 5 µM (B), collagen 4 µg/mL 
(C) or TRAP-6 25 µM (D) in channels of the luminescence aggregometer. 
ATP release was measured as an indicator of platelet activation and 
quantified using an ATP spike as outlined fully in section 5.2.4. There was 
a significant reduction in collagen-induced ATP release from platelets 






Figure 5.6 Maximum ATP release in response to various agonists of 
platelets derived from a cPLA2α mutated patient or healthy controls  
 
ATP release from platelets stimulated with arachidonic acid 1 mM (A), 
ADP 5 µM (B), collagen 4 µg/mL (C) or TRAP-6 25 µM. Results displayed 
as mean ± SEM. Two samples were obtained from the test patient on two 






























































































5.3.4 Activation of platelets from a cPLA2α mutated patient – surface 
P-selectin expression 
 
Whole blood was incubated with EDTA vehicle, ADP 40 µM, 
U46619 0.5 µM or a combination of both in a 96 well plate as described in 
section 5.2.5 and flow cytometry used to obtain mean fluorescence 
intensity values of cell surface P-selectin (CD62P). Data presented in 
Figure 5.7 indicates that the patient sample has an increase in P-selectin 
expression compared to controls when stimulated with either U46619 
alone or in combination with ADP. The n=1 patient sample prohibits the 





Figure 5.7 Flow cytometric analysis of agonist stimulated P-selectin 
expression in platelets from a cPLA2α mutated patient compared to 
healthy controls 
 
Mean florescence intensity values for P-selectin (CD62P) expression per 
100,000 CD61 positive platelet events. Results displayed as mean ± SEM 

























EDTA    -          +         +        +           +
ADP    -           -         +          -        +
U46619    -           -         -         +        +
CONTROL
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5.3.5 Pre- and post-sequencing sample assessment  
 
Pre- and post-sequencing analyses of the RNA input, cDNA libraries and 
aligned reads required for RNA-Seq are essential to decisions regarding 
which samples to take forward into differential expression calculations.   
 
RNA quality was assessed using the total RNA pico chips and reagents 
for the Agilent 2100 Bioanalyser that produces a normalised value, called 
the RNA integrity number (RIN), allowing direct comparisons between 
samples. RNA samples are given a RIN between 1-10 with 1 being the 
most and 10 being the least degraded, as calculated using Agilent 
patented algorithms available on the Bioanalyser software which takes 
into account multiple features of the electrophoretic trace. All samples, 
had an acceptable RIN value of >6.5. Full-length cDNA molecules were 
generated from 1ng of total RNA per sample using the SMARTer kit that 
includes a poly-A selection step to enrich samples for protein coding 
genes, a cDNA amplification step using PCR and an adaptor removal 
step in order to produce cDNA libraries for each sample. Libraries where 
then quantified in terms of molarity and average size using the QuBit 
fluorometer. For RNA-Seq differential expression applications it is 
preferable that the library molarity is greater than 3 nM (libraries are then 
diluted to achieve the same molarity for all libraries) and that the library 
size is 300-500 bp. Column 2 in Table 5.2 shows the library molarity in 
nmol for each sample and column 3 in Table 5.2 shows the average 
library size in bp for each sample 
 
Sequencing coverage describes the average number of reads that align 
to known reference bases, the number of reads required depends upon 
what sensitivity is required to detect genes expressed at low levels. 
Owing to the fact that many functionally important platelets genes are 
expressed at a low level the decision was made to use a depth of 
coverage of 40 million reads per sample. Column four in table 5.2 shows 
the total number of reads for each sample, with all samples apart from 
patient replicate 2 have acceptable values ranging from 28-39 million of 
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which between 89-91% of those align to the reference genome (column 
five Table 5.2). For these reasons patient replicate 2 sample highlighted 
in yellow was removed for the subsequent differential expression analysis 
(Table 5.2). All samples evenly distributed the number of aligned reads to 
each of the two DNA strands as indicated by the percentage of aligned 
reads to each strand being 50%. The decision to perform un-stranded 
RNA-Seq was made as for differential expression analysis it is not 







Table 5.2 RNA-Seq sample quality analyses  
 
Parameters commonly measured to ensure sample quality; RNA integrity 
number, library molarity (nM), library average size (bp), number of reads, 




























Control	1 8.4 5.56 394 39,436,367 90.66% 50.10%
Control	2	 7.8 1.86 369 29,959,188 90.15% 50.13%
Control	3 6.9 3.80 364 38,417,943 89.85% 50.24%
Control	4 6.7 1.50 335 30,635,690 90.02% 50.24%
Control	5 6.8 1.98 336 32,767,537 90.51% 50.20%
Control	6 7.4 0.61 306 28,818,265 89.95% 50.14%
Patient	replicate	1 7.4 1.60 319 34,300,286 90.53% 50.29%
Patient	replicate	2 7.2 0.10 237 8,037,788 83.30% 50.00%
Patient	replicate	3 N/A 1.43 308 30,133,687 88.48% 50.21%
Patient	replicate	4 6.8 2.32 324 29,872,748 90.40% 50.21%
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5.3.6 Comparing RPKM values obtained using RNA-Seq against a 
previously published data set 
 
Reads per kilo base per million (RPKM) are quantitative approximations 
of the abundance of all target transcripts. RNA-Seq provides this 
quantification in the form of raw counts from which RPKM values can be 
calculated as a way of removing biased estimations of transcript 
abundance inherent to the sequencing process.  For example longer 
transcripts will have more reads mapped to their region as there are more 
bases there to begin with, this would bias comparisons of genes of 
different length. RPKM values are calculated in three steps: 1) count the 
total reads in a sample and divide by 1,000,000 to give the ‘per million’ 
scaling factor; 2) divide the read counts for each gene by the ‘per million 
scaling factor’ to give the ‘reads per million’, this step normalises for 
difference in sequencing depth; and 3) divide the ‘reads per million 
values’ for each gene by the length of the gene in kilobases to derive the 
RPKM value.  
 
In order to understand how the data compared to other platelet RNA-Seq 
studies a comparison was made between these current results and 
results produced by Rowley et al in their 2011 study titled “Genome-wide 
RNA-seq analysis of human and mouse platelet transcriptomes” 54. 
Working from the logged RPKM values from each of the six healthy 
control data sets an average log-RPKM value for each expressed gene 
was calculated.  
 
Using the average control values the data was sorted based on log 
RPKM values ordered highest to lowest. The top 40 expressed genes 
were taken, ranked 1-40 with rank number 1 being the most abundant 
(Table 5.3 columns 1 (gene names) and 2 (ranking)) and directly 
compared to the top 40 expressed genes published in the Rowley study 
(Table 5.3 columns 3 (gene names), 4 (ranking in my control data set). 
The average patient top 40 (Table 5.4 column 1) was then compared to 
both the control top 40 (Table 5.4 column 2) and the Rowley study top 40 
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(Table 5.4 column 3). Values highlighted in orange indicate a ranking that 
falls outside of the top 40. Values assigned with ‘?’ indicates a ranking 
that was not in the published data set. Tables 5.3 and 5.4 shows that 
there was a good similarity between the control and patient data sets as 
well as between the current data sets and the historical Rowley study 





Table 5.3 Comparing the top 40 most highly expressed genes in 
control versus patient PRP samples – My control data set versus 
Rowley data set 
 
Log RPKM values were used to rank genes according to their 
abundance. This ranking was used to compare control data obtained in 
this current study (blue) to data published in another platelet RNA-Seq 









TMSB4X 1 MIR1978 ?
B2M 2 B2M 2
FTH1 3 MIR1974 ?
PPBP 4 FTH1 3
ACTB 5 PF4 7
OST4 6 PPBP 4
PF4 7 NRGN 19
HBB 8 OST4 6
HBA2 9 HIST1H2AC 24
FTL 10 ACTB 5
GNG11 11 GP1BB 25
SH3BGRL3 12 FTL 10
TAGLN2 13 OAZ1 16
TUBB1 14 GPX1 27
SDPR 15 HLA-E 119
OAZ1 16 TUBB1 14
RGS18 17 GNAS 6040
H3F3AP4 18 TAGLN2 13
NRGN 19 CLU 30
SPARC 20 SDPR 15
MYL12A 21 CCL5 31
F13A1 22 SH3BGRL3 12
MYL6 23 SPARC 20
HIST1H2AC 24 F13A1 22
GP1BB 25 HBB 6494
MAP3K7CL 26 PPDPF 174
GPX1 27 FLNA 237
H3F3A 28 MYL6 23
ARPC1B 29 PGRMC1 36
CLU 30 HLA-B 190
CCL5 31 CALM3 95
ITM2B 32 ITGA2B 55
PTMA 33 TLN1 152
SAT1 34 TGFB1 219
LOC101927854 35 MYL9 121
PGRMC1 36 HLA-C 613
PRKAR2B 37 ARPC1B 29
HIST1H3H 38 ITM2B 32
MMD 39 RGS18 17
CA2 40 ITGB3 520
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Table 5.4 Comparing the top 40 most highly expressed genes in 
control versus patient PRP samples 
 
Log RPKM values were used to rank genes according to their 
abundance. This ranking was used to compare the top 40 genes 
expressed in the cPLA2α data set with the top 40 genes expressed in the 
control data sets generated in this experiment and as published by 
















































5.3.7 Differential expression analysis  
 
Using the RPKM values for the averaged control data set and the 
averaged patient data set a one-way ANOVA with p=<0.0001 was used 
to determine which genes were differential expressed between control 
and patient. Fold changes were expressed using the log 2 scale.  
 
Table 5.3 shows all statistically different differentially expressed genes, 
their chromosomal location, P-values, mean ratio (the ratio of the mean 
values of RPKMs of the two groups, numbers less than 1 indicate down 





















































49727	KB	(-	strand) 3.75E-05 0.033 -30.547
DSC2 Desmocollin	2
Chr	18	starting	at	






19156	KB	(+	strand) 1.10E-05 0.044 -22.682
APOL4 Apolipoprotein	L4
Chr	22	starting	at	

















50172	KB	(+	strand) 8.91E-05 0.071 -14.172
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Table 5.5 Differentially expressed genes: Control versus Patient  
 
The 26 differentially expressed genes in the control samples compared to 
the patient samples. A one-way ANOVA p=<0.0001 was used to test 

























24122	KB	(-	strand) 3.64E-05 0.102 -9.795
KRT23 Keratin	23
Chr	17	starting	at	
















































153357	KB	(+	strand) 2.35E-05 0.298 -3.351
GCA Grancalcin
Chr	2	starting	at	
162318	KB	(+	strand	) 7.51E-05 0.381 -2.624
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Discussion 5.4  
 
Group IV A cytosolic phospholipase A2 (cPLA2α) is a calcium-activated 
enzyme that preferentially binds arachidonic acid over other available 
fatty acids. Phosphorylation of this enzyme by mitogen activated protein 
kinases following agonist stimulation enables the translocation of cPLA2α 
from the cytoplasm to the membrane of cells where it can exert its 
enzymatic functions 183.   
 
The enzymatic actions of the phospholipase A2 (PLA2) family of proteins 
are critical to the production of important eicosanoids within the 
cardiovascular system. PLA2 enzymes catalyse the hydrolysis of 
membrane phospholipids to release arachidonic acid which is then further 
broken down into its active eicosanoids via specific enzymatic pathways 
172.  
 
In this chapter I obtained blood samples from a patient with a mutation in 
PLA2G4A gene that causes inactivation of the cPLA2α enzyme, in order 
to specifically assess platelet function compared to healthy controls. 
 
Previous investigations carried out on this patient have shown that loss of 
cPLA2α activity has significant negative effects on eicosanoid production 
that subsequently diminishes platelet aggregation and ATP release 168. In 
a study focussed on the specific cardiovascular effects of this mutation 
investigators showed an absolute requirement for cPLA2α in eicosanoid 
synthesis. By assessing effects on platelets, leukocytes and endothelial 
cells it was shown that lack of eicosanoid production caused a 
consequent loss in platelet activation, reduced antithrombotic prostacyclin 
and increased inflammatory sensitivity of both endothelial cells and 
leukocytes 184. Supportive work using the specific pharmacological 
inhibitor for the cPLA2α isoform, pyrrophenone, has demonstrated this 
enzyme’s role in arachidonic acid release and subsequent eicosanoid 
synthesis using whole blood assays 185,186. Additionally cPLA2α -/- mice 
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display phenotypes, including protection against thromboembolism, 
prolonged bleeding, protection from asthma and reduced incidences of 
certain cancers all of which can be explained by the lack of eicosanoid 
production 187–192. Studies using these animals further highlight the 
importance of the cPLA2 enzyme to the production of bioactive lipids 193–
195.   
 
In this current investigation I used traditional light transmission 
aggregometry (LTA) and the Optimul plate assay to assess platelet 
aggregation in response to the agonists arachidonic acid, ADP, collagen, 
epinephrine, ristocetin, TRAP-6 and U46619. In the LTA assay there was 
significant reduction in percentage aggregation recorded in response to 
ADP 20 µM, collagen 0.4 µg/mL and collagen 4 µg/mL (Figure 5.4). 
Acting through the cell surface receptors P2Y12 and P2Y1, ADP causes 
platelet aggregation, platelet intracellular calcium mobilisation, platelet 
shape change and release of granule content 196–198. ADP activation also 
stimulates TXA2 production that then feeds-back on the platelet to further 
increase the activating response 41. Thus in this patient there was a 
decreased response to ADP due to the lack of TXA2 production from 
arachidonic acid. Similarly collagen activation of platelets is enhanced by 
the production of TXA2 stimulated by a rise in intracellular calcium 199–201. 
Hence the significant reduction in aggregation seen for this patient 
particularly in response to the lower concentrations of collagen used 
(0.4 and 4 µg/mL).  
 
Likewise ATP release from the patient’s platelets was significantly lower 
for collagen 4 µg/mL stimulated samples in the luminescence 
aggregometry based assay (Figure 5.6) as collagen is also known to 
stimulate platelet granule secretion partly through the production of TXA2 
202.   
 
In addition to this there was significant reduction in percentage 
aggregation recorded in response to epinephrine and U46619 across the 
concentration ranges used in the Optimul plate assay (Figure 5.5). 
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Epinephrine has been shown to increase the release of TXA2 from 
platelets 203–205, as the patient cannot produce this eicosanoid the 
reduction in aggregation is as expected. Although U46619 is a synthetic 
stable TXA2 receptor agonist there is still a diminished response to this 
agonist in platelets from the test patient owing to the lack of secondary 
TXA2 release in response to the initial agonist stimulation 206, which can 
be seen in the midpoint of the agonist response curve.  
 
The increase in platelet activation, as measured by P-selectin expression, 
in response to U46619 or ADP stimulation was significantly increased in 
the patient compared to the controls (Figure 5.7). This could potentially 
hint towards a compensatory mechanism whereby the platelets increase 
their ability to form platelet-leukocyte aggregates as a response to the 
loss of TXA2 mediated platelet-platelet aggregation. Further investigations 
are required to fully test this hypothesis as it is based on a single 
observation.   
 
As well as testing the function of platelets obtained from the cPLA2α 
mutated patient I compared the platelet mRNA expression profiles 
between patient and control samples using RNA-Seq in combination with 
the optimised protocol for platelet isolation as described in chapter 3. The 
rationale for mRNA sequencing platelets from this patient was to 
investigate whether the lack of cPLA2α protein activity and subsequent 
changes in bioactive eicosanoid production affects platelet mRNA 
expression. I hypothesised that platelets from this patient could show 
changes in expression of genes related to the arachidonic 
acid-eicosanoid pathway of platelet activation such as reductions in 
synthase enzymes, due to reduced substrate, and decrease in receptors, 
due to reduced agonists. It is interesting to note that the PLAG4A gene 
appears at rank number 4763 in my control data set and at rank number 
7009 in the patient data set suggesting that lack of cPLA2α protein activity 
could as a consequence be having a negative feedback on PLAG4A 
mRNA expression within the platelet.  
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Using differential expressions analysis I found 26 transcripts that were 
significantly upregulated in the patient platelet samples compared to 
control (Table 5.5). Of these 26 transcripts, 4 (S100A8, S100A9, 
S100A12 and SLP1) had previously been linked to aspects of platelet 
biology and would thus be interesting targets for further investigation.  
 
S100A8, A9 and A12 are all genes that encode for low molecular weight 
calcium binding proteins. As a whole the S100 family of proteins function 
to regulate a variety of intracellular and extracellular processes including 
proliferation, differentiation, migration, apoptosis, calcium homeostasis, 
energy metabolism and inflammation. The S100 proteins, of which there 
are thirteen, all cluster on chromosome 1q21. S100A8, A9 and A12 
proteins all have very similar functions and play prominent roles in the 
regulation of the immune system and in the inflammatory response. As 
such these proteins help to induce leukocyte chemotaxis, adhesion, 
degranulation, phagocytosis whilst also possessing pro-inflammatory, 
antimicrobial, oxidant-scavenging and apoptosis-inducing activities 207–210.  
 
The S100A8, A9 and A10 gene products are referred to by various 
names in the literature. The S100A9 protein is also known as migration 
inhibitory factor-related protein-14 (MRP-14) or as calgranulin A, likewise 
the S100A8 protein is also known as MRP-8 or calgranulin B. Together 
the S100A9 and S100A8 protein form a heterodimer called calprotectin 
(MRP-8/14).  
 
MRP-8/14 levels have been linked to numerous inflammatory disease 
states including many cardiovascular disease processes 211. In 2006 in a 
study profiling platelet mRNA from patients with acute ST-segment 
elevation myocardial infarction (STEMI) or stable coronary artery disease 
(CAD) investigators reported a significant increase in MRP-14 at the 
mRNA level and a consequent significant increase in plasma levels of the 
MRP-8/14 heterodimer in the STEMI patients compared to the stable 
CAD patients. Following on from this the group then sought to validate 
the MRP-14 gene target in a group of 28,345 healthy postmenopausal 
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women in order to assess the risk of future cardiovascular events 
associated with plasma levels of the MRP-8/14 heterodimer. At the end of 
the three-year follow up period it was shown that initially healthy women 
who subsequently developed cardiovascular events during follow-up had 
higher median MRP-8/14 levels at baseline than women who remained 
free of disease. After various risk correction analyses it was 
demonstrated that having an MRP-8/14 level in the top quartile equated 
to a 4-fold elevation in risk for all cardiovascular events 212.   
 
Two years later another study sought to investigate the risk of 
cardiovascular death or myocardial infarction associated with MRP-8/14 
measured 30 days after an acute coronary syndrome event. What they 
found was that patients who died as a result of a cardiovascular event or 
who had had a myocardial infarction after the 30 days had higher levels 
of MRP-8/14 compared to patients who remained free of recurrent events 
213.  
 
Other groups have also linked increased platelet MRP-8/14 protein and 
serum levels to systemic lupus erythematosus patients who also have 
cardiovascular disease 214,215.  
 
In an attempt to strengthen the link between MRP-8/14, cardiovascular 
disease risk and thrombosis, investigators used wild-type mice to show 
that platelets up-regulate expression of MRP-8/14 and increase secretion 
of MRP-8/14 during arterial thrombosis and that this can signal through 
CD63 on other platelets to drive the thrombus formation. They also 
obtained arterial thrombi from STEMI patients and found that they stained 
positive for the MRP-14 protein 216. Further evidence suggests that 
MRP-8/14 levels, in particular reference to acute coronary syndrome 
patients, were linked to enhanced TXA2 dependent platelet activation 217 
and that more generally serum MRP-8/14 levels correlate positively with 
platelet aggregation 218.     
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To a lesser extent increased expression of S100A12 has also been linked 
to increased cardiovascular disease risk in the context of determining 
atherosclerotic plaque rupture risk. However S100A12 was only 
measured as protein levels in the serum with no evidence to support that 
this was derived from platelets 219. 
 
Together these studies provide evidence to support the further 
investigation of MRP-8/14 as a biomarker or therapeutic target for future 
cardiovascular events linked to thrombosis and reinforces the idea that 
the platelet transcriptome can be used as a source of disease 
biomarkers. MRP-8/14 blockers have been developed and are approved 
for clinical testing 211,220.  
 
It is interesting then that the cPLA2α deficient patient presented in this 
chapter had significantly up-regulated platelet expression of these three 
genes. One possible explanation is that this may be a compensatory 
mechanism for the lack of eicosanoid driven platelet activation. While 
more evidence is needed to substantiate this idea, the patient’s strong 
aspirin-like phenotype yet lack of bleeding symptoms is supportive. 
Furthermore there is evidence from groups working on human neutrophils 
showing that the MRP-8/14 complex binds arachidonic acid and thus 
provides an intracellular reservoir of arachidonic acid for the cell 221. 
When combining this knowledge with the fact that endothelial cells have 
the ability to utilise exogenous arachidonic acid for trans-cellular 
production of thromboxane 222 it could be speculated that platelets could 
also take up arachidonic acid from other cell type for its metabolism into 
functionally important eicosanoids. This would be particularly relevant in 
the case of the cPLA2α deficient patient whose platelets lack the ability to 
liberate arachidonic acid from the cell membrane but retain the ability to 





The SLPI (secretory leukocyte protease inhibitor) transcript, which was 
up-regulated in the patient samples, has also been shown to modulate 
platelet function. Rap-1 (Ras-related protein-1) plays a key role in platelet 
activation as shown previously by multiple groups 223–225. In platelets 
Rap-1 activity is regulated by the GTPase activating protein Rap1GAP2 
226. SLPI is a binding partner for Rap1GAP2 and has been shown to 
inhibit dense granule release in human platelets 227. The test patient did 
indeed show a reduced dense granule ATP release response that could 
be partially explained by the increase in SLPI expression. However 
further experiments would be needed to separate out the effects of SLPI 
over-expression and lack of TXA2 signalling which could both be 
contributing to the diminished platelet release response. Located at 
chromosome position 20q13.12 SLPI’s most well documented function is 
in the immune system where is protects mucosal epithelial surfaces from 
serine proteases 228. 
 
An obvious progression of the differential expression data would have 
been to perform pathway analysis of the significantly up/down regulated 
transcripts. Unfortunately due to there being only 26 such transcripts in 
my data set there was not enough statistical power to provide meaningful 
results. However performing a basic enrichment analysis search using 
the Gene Ontology Consortium online tool produced a list of 
over-represented functional classes within those 26 gene with the top five 
being immune system process, immune response, exocytosis, secretion 
by cell and secretion. As already described SLPI has a clear link to the to 
secretion terms whereas the roles of S100A8, A9 and A10 have quite 
obvious links to an immune system process, namely inflammation.  
 
In conclusion lack of cPLA2 enzymatic activity results in the loss of 
eicosanoid production from arachidonic acid. This in turn has significant 
effects upon various aspects of platelet function including aggregation 
and granule release. In addition RNA-Seq of platelets obtained from this 
patient revealed a number of differentially expressed transcripts when 
compared to control sample four of which (S100A8, S100A9, S100A12 
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and SLPI) have previously been linked to the regulation of platelet 
function, thrombosis and cardiovascular disease risk making them 













Chapter 6 - Assessment of platelet function 
in patients with bleeding disorders featuring 








Bleeding and platelet disorders (BPD) are a group of diseases caused by 
defects to the coagulation system, platelets or vessel walls often 
presenting as abnormal bleeding. The heterogeneous nature and rarity of 
these conditions makes clinical diagnosis and management difficult. 
Current clinical diagnostic tools can pinpoint the cause of a BPD in 
around 40-60% of cases and only a fraction of these receive a genetic 
diagnosis owing to the fact that the genetic basis of BPDs are mostly 
unknown.  
 
As part of the larger BRIDGE-BPD consortium this chapter aims to 
investigate the use of in depth platelet function testing for patients with 
bleeding disorders of unknown aetiology or with confirmed mutations 
predicted to alter platelet function in order to provide better phenotypic 
information, enabling more accurate diagnoses. The BRIDGE-BPD study 
is an observational multicentre study that aims to identify causal gene 
mutations in patients with BPDs by using next generation sequencing 
technologies. The study inclusion criteria are as follows; platelet count of 
less than 100 x 10(9)/L or greater than 400 x 10(9)/L, or mean platelet 
volume less than 6 fL or greater than 12 fL, or reproducible abnormal 
platelet function tests, or abnormal platelet morphology by light or 
electron microscopy, or pathological bleeding of unknown aetiology, and 
considered by referring clinician to be of genetic aetiology. The study 
exclusion criteria are as follows; acquired bleeding or platelet disorder 
including any of the following: use of any medication known to affect 
platelet function, immune thrombocytopenia, HIV infection, malignancies, 
bone marrow aplasia, thrombotic thrombocytopenic purpura / 
haemolytic-uremic syndrome, acute viral infection, splenomegaly and 
uraemia or hepatic failure.  
 
In particular this chapter focuses on a family consisting of an index case 
with a homozygous mutation in the PTGS1 gene encoding for the 
cyclooxygenase-1 enzyme (COX-1) and their reportedly asymptomatic 
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parents. The index patient was identified at The Royal London Hospital 
(Barts Health NHS Trust) presenting with cystic fibrosis with recurrent 
respiratory infections, complement component-6 deficiency, recurrent 
miscarriages, haemoptysis, epistaxis, peri-operative bleeding and a 
tendency to bruise easily. As a consequence the index patient is treated 
with desmopressin, tranexamic acid and antibiotics when required. The 
parents are consanguineous and present with no current or historical 
symptoms of bleeding. They take no medications known to alter platelet 
function.  
 
The PTGS1 gene encodes for the cyclooxygenase-1 protein (COX-1) 
also known as prostaglandin G/H synthase-1. The enzyme itself consists 
of two catalytic sites the cyclooxygenase site to which arachidonic acid 
binds and the peroxidase site to which prostaglandin G2 binds. Figure 6.1 
outlines the conversion of arachidonic acid, through the activity of platelet 
COX-1, into various eicosanoids. The COX-1 enzyme works downstream 
of the PLA2 enzymes, as discussed in the previous chapter, to produce 
biologically active eicosanoids that are essential to platelet function, 
through the metabolism of arachidonic acid 177. The mutation identified in 
the index case was a homozygous missense mutation G>C found on 
chromosome 9 resulting in a tryptophan to serine amino acid change 
within exon 8. A representation of the location of this mutation can be 
seen in Figure 6.2. This figure, created using the UCSC genome browser 
and mapped to the Human February 2009 (GRCh37/hg19) assembly, 
shows the location of the PTGS1 gene to be on the long arm of 
chromosome 9 with the patient’s mutation occurring at position 
125132069. Based on the H3K4Me1 and H3K27Ac signals overlaid on 
Figure 6.2 in blue/pink the mutation does not appear to be within these 
chromatin domains that are highly associated with activation and 
repression of gene translation. Thus the mutation is unlikely to affect 
transcription of the PTGS1 gene These observation fall in line with the 
fact that the mutation is an exonic variant which is expected to have a 
direct effect on the protein rather then its regulation. It should be noted 
that the variant is in a highly conserved area. Thus indicating that this 
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mutation will likely have a functional effect upon the cycol-oxygenase-1 
protein.  
 
This chapter will investigate the functional consequences to the platelet of 
this specific mutation by comparing the patient data to both the 






Figure 6.1 Outline of COX-1 catalytic sites  
Schematic showing the conversion of arachidonic acid to biologically 

































































































































































































































































6.2 Methodology  
 
6.2.1 Blood collection, preparation of PRP and BRIDGE-BPD study  
 
Blood was obtained from healthy volunteers or patients of interest and 
PRP/PPP prepared as outlined previously in sections 3.2.1 and 3.2.2.  
Bleeding disorder patients were recruited as part of the BRIDGE-BPD 
study approved by a UK Research Ethics Committee (Cambridgeshire 1 
Research Ethics Committee 10/H0304/66). All study procedures were 
performed after the participants provided informed written consent and 
were in accordance with the Declaration of Helsinki.  
 
6.2.2 Light transmission aggregometry (LTA) agonist stimulation of 
PRP  
 
225 µL of PRP was added to add to each test cuvette, placed into the 
PAP8-E aggregometer and stimulated with 25 µL of agonist as described 
in section 3.2.6 to achieve final concentrations of arachidonic acid 1 mM, 
ADP 10 µM, collagen 1 µg/mL, collagen 3 µg/mL, TRAP-6 25 µM, 
U46618 3 µM, epinephrine 10 µM or ristocetin 1.5 mg/mL. 
 
6.2.3 Optimul plate assay 
 
Optimul plates were prepared according to section 3.2.7. Upon use of the 
plate, 40 uL of PRP or PPP are added to the appropriate wells, the plate 
is shaken on a Bioshake plate shaker at 1200 rpm, for 5 min and 37°c 
and the absorbance is read at 595 nm on a Tecan Sunrise plate reader. 
Agonists used were ADP (0.005-40 µM), epinephrine (0.0004-10 µM), 
TRAP-6 amide (0.03-40 µM), U46619 (0.055-40 µM), arachidonic acid 
(0.03-40 µM), ristocetin (0.14-4 mg/mL) and Horm collagen 
(0.01-40 µg/mL). 
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6.2.4 Luminescence (lumi) aggregometry – ATP release 
 
225 µL of PRP was added to add to each test cuvette, placed into the 
lumi aggregometer and stimulated with 25 µL of agonist as described in 
section 5.2.4 to achieve final concentrations of arachidonic acid 1 mM, 
ADP 10 µM, collagen 3 µg/mL or TRAP-6 25 µM. Maximum ATP release 
was recorded and calculated as outlined in Figure 5.3.  
 
6.2.5 Platelet surface P-selectin expression – whole blood 
 
A flow cytometric assay was used to assess platelet surface P-selectin 
(CD62P) expression in whole blood samples as an indicator of platelet 
activation in response to ADP (40 µM) or U46619 (0.5 µM) stimulation as 
described in 5.2.5.  
 
6.2.6 Quantifying COX-1 protein expression using confocal imaging  
 
2 mL of PRP was fixed in 1 mL of 8% paraformaldehyde in PBS 
(PFA-PBS) for 15 min at room temperature. Platelets were then pelleted 
at 900 x g for 10 min and the supernatant removed. The platelet pellet 
was then resuspended in 2 mL of acid citrate dextrose PBS buffer 
(ACD-PBS) at pH 6.1 and centrifuged again at 900 x g for 10 min. The 
pellet was resuspended again in ACD-PBS and centrifuged again at 
900 x g for 10 min. The supernatant was removed and the pellet 
resuspended in 1 mL of 1% BSA in PBS. The platelets were then pipetted 
onto glass cover slips and incubated at 37°C for 90 min. Cover slips were 
then rinsed three times with PBS and blocked with a solution containing 
0.2% Triton, 2% donkey serum and 1% BSA for 1 hour. A primary 
antibody mix containing rabbit anti-COX-1 (1:100) and mouse anti-tubulin 
(1:100) diluted in 0.2% Triton, 2% donkey serum and 1% BSA was 
pipetted onto the coverslips and left to incubate overnight at room 
temperature. Coverslips were washed in the morning three times with 
PBS and incubated with Alexa647 anti-rabbit (1:500) and Alexa488 
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anti-mouse (1:500) secondary antibodies for 1 hour at room temperature. 
The coverslips were then washed again three times in PBS and then 
fixed with 4% PFA-PBS for 5 min and washed again three times in PBS. 
The coverslips were then mounted onto glass slides using ProLong 
Diamond anti-fade mountant and left to dry for 1 hour at room 
temperature before storing at 4°C until imaging.   
 
Confocal fluorescence microscopy images were obtained with oil 
immersion objectives (CFI Plan Apochromat 100 X, N.A.1.4, working 
distance 0.17 mm) using the LSM 710 confocal microscope. The 
microscope is equipped with 4 lasers: diode laser 405 nm 30 mW, 
multi-line argon lase 458/488/514 nm 25 mW, HeMe 543 nm 1 mW and 
HeNe 633 nm 5 mW. Acquisition and image processing were performed 
using the ZEN 2009 software. 
 
6 images were analysed taken using the x100 oil immersion lens with a 
2.5 zoom. For each image 10 platelets were randomly selected for 
analysis. Using ZEN software enabled quantification of the brightness of 
both the tubulin (green) and COX-1 (red) stains. These values were 
averaged to produce a single value for all six control images versus all six 
patient (386Q) images. There was no significant difference between 
COX-1 staining intensity between patient and control (Figure 6.14) 
indicating that the mutation is unlikely to cause a loss of protein 
expression. A t-test was used to determine significance (p=0.05).  
 
6.2.7 Liquid chromatography tandem mass spectrometry 
(LC-MS/MS) analysis of agonist stimulated whole blood  
 
Whole blood was stimulated with collagen 30 µg/ml or vehicle in the 
PAP8E aggregometer for 30 min at 37°C whilst being continually stirred. 
30 µL of diclofenac/heparin solution (31.8 mg diclofenac sodium salt, 
8.8 mL phosphate buffered solution, 200 uL heparin) was then added to 
each cuvette to stop the reaction. The contents of the cuvettes were 
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transferred into 1.5 mL Eppendorf tubes and centrifuged at 1000 x g. 
Supernatants (200 µL) were removed and stored at -80°C until required. 
 
Samples were sent to Matthew Edin at The National Institutes of Health, 
National Institute of Environmental Health Science, North Carolina, USA 
for liquid chromatography tandem mass spectrometry analysis as 
described fully in 4.2.8.   
 
6.2.8 Statistical analysis 
 
All statistical analyses were conducted used GraphPad Prism v6 and are 






6.3.1 Determining control ranges for LTA measured platelet 
aggregation in response to various agonists  
 
LTA as described in 5.2.2 was used to determine aggregation responses 
for twenty healthy control samples in order to produce reference 
percentiles to compare the bleeding disorder patient samples. PRP was 
stimulated in the aggregometer and percentile ranges produced for 
aggregation in response to arachidonic acid 1mM (Figure 6.3 A, 
Figure 6.4 A), ADP 10 µM (Figure 6.3 B, Figure 6.4 B), collagen 1 µg/mL 
(Figure 6.3 C, Figure 6.4 C), collagen 3 µg/mL (Figure 6.3 D, Figure 6.4 
D), TRAP-6 25 µM  (Figure 6.3 E, Figure 6.4 E), U46619 3 µM (Figure 6.3 
F, Figure 6.4 F), epinephrine 10 µM (Figure 6.3 G, Figure 6.4 G) and 




Figure 6.3 LTA aggregation responses for twenty healthy controls  
 
Percentage final aggregation responses measured using LTA in response 
to arachidonic acid (A), ADP (B), collagen (C and D), TRAP-6 (E), 
U46619 (F), epinephrine (G) and ristocetin (H). Results displayed as 
individual data points for each control with overlaid percentile indicators 
(dotted lines).   


























































































































































































































Figure 6.4 LTA aggregation responses for twenty healthy controls: 
percentile tables  
 
Percentage final aggregation responses measured using LTA in response 
to arachidonic acid (A), ADP (B), collagen (C and D), TRAP-6 (E), 
U46619 (F), epinephrine (G) and ristocetin (H). Results for PRP prepared 

































































































6.3.2 Determining control curves for Optimul plate measured platelet 
aggregation in response to various agonists  
 
The Optimul plate assay, as described in 3.2.7, was used to determine 
aggregation responses for twenty healthy control samples in order to 
produce reference percentiles to compare the bleeding disorder patient 
samples. PRP was stimulated in the pre-prepared 96 well plates and 
percentile ranges produced for aggregation in response to multiple 
concentrations of arachidonic acid 0.03-40 µM (Figure 6.5 A), ADP 
0.005-40 µM (Figure 6.5 B), collagen 0.01-40 µg/mL (Figure 6.5 C), 
epinephrine 0.0004-10 µM (Figure 6.5 D), ristocetin 0.14-4 mg/mL 
(Figure 6.5 E), TRAP-6 0.03-40 µM (Figure 6.5 F) and U46619 






Figure 6.5 Optimul plate aggregation response curves for twenty 
healthy controls  
 
Percentage final aggregation responses measured using the Optimul 
plate assay in response to concentration ranges of arachidonic acid (A), 
ADP (B), collagen (C), epinephrine (D), ristocetin (E) TRAP-6 (F) and 
U46619 (G) Results for PRP prepared from twenty healthy control 
subjects.  






































































































































6.3.3 Determining control ranges for ATP release measured in 
response to various agonists 
 
A luminescence aggregometry assay, as described in 5.2.4, was used to 
determine maximum ATP release values in order to generate reference 
percentiles to compare bleeding disorder patient samples. Percentile 
ranges were produced for ATP release in response to arachidonic acid 
1 mM (Figure 6.6 A, Figure 6.7 A), ADP 10 µM (Figure 6.6 B, Figure 
6.7 B), collagen 3 µg/mL (Figure 6.6 C, Figure 6.7 C) and TRAP-6 25 µM 






Figure 6.6 Agonist stimulated ATP release for twenty healthy 
controls  
 
Max ATP release (nmol) in response to arachidonic acid (A), ADP (B), 
collagen (C) and TRAP-6 (D). Results displayed as individual data points 





















































































































Figure 6.7 Agonist stimulated ATP release for twenty healthy 
controls: percentile tables 
 
Max ATP release (nmol) measured using a lumi aggregometer in 
response to arachidonic acid (A), ADP (B), collagen (C) and TRAP-6 (D). 


























































6.3.4 Determining control ranges for whole blood P-selectin 
expression measured in response to various agonists 
 
A whole blood flow cytometric assay for the determination of platelet 
surface P-selectin (CD62P) expression, as described in 5.2.5, was used 
to determine mean florescence intensity values for P-selectin in order to 
produce reference percentiles against which to compare the bleeding 
disorder patient samples. Whole blood was stimulated in the wells of a 96 
well plate containing the agonist and percentile ranges were produced for 
P-selectin expression in response to vehicle (Figure 6.8 A, Figure 6.9 A), 
ADP 40 µM (Figure 6.8 B, Figure 6.9 B), U46619 0.5 µM (Figure 6.8 C, 
Figure 6.9 C) or ADP 40 µM + U46619 0.5 µM (Figure 6.8 D, 





Figure 6.8 Agonist stimulated surface P-selectin expression for 
twenty healthy controls  
 
Mean fluorescence intensity values of platelet surface P-selectin 
expression in samples treated with vehicle (non-stimulated, A), ADP (B), 
U46619 (C) or ADP+U46619 (D) measured using a flow cytometric 
assay. Results displayed as individual data points for each control with 







































































































































































Figure 6.9 Agonist stimulated surface P-selectin expression for 
twenty healthy controls: percentile tables 
 
Mean fluorescence intensity values of platelet surface P-selectin 
expression in non-stimulated samples (A) or samples stimulated with 
ADP (B), U46619 (C) or ADP+U46619 (D) measured using a flow 




















































6.3.5 LTA measured platelet aggregation – COX-1 mutated family + 
healthy control percentiles  
 
LTA as described in 5.2.2 was used to determine aggregation responses 
for the COX-1 mutated index case (386Q; green) and the two parents 
(394Q; pink and 395O; blue). Each individual was tested in duplicate, by 
collection of two blood samples on two separate days, and compared to 
the control percentiles defined in section 6.3.1 (Figure 6.10).  
 
In response to arachidonic acid index 386Q and parent 394Q had final 
percentage aggregation values that fell below the 10th percentile of 
healthy control responses, parent 395O fell below the 50th percentile 
(Figure 6.10 A). In response to ADP index 386Q fell below the 10th 
percentile, parent 394Q fell below the 20th percentile and parent 395O fell 
below the 50th percentile (Figure 6.10 B). In response to low 
concentration collagen index 386Q and parent 394Q fell below the 10th 
percentile whereas parent 395O fell below the 20th percentile (Figure 6.10 
C). In response to the higher concentration of collagen index 386Q and 
parent 394Q still fell below the 10th percentile whereas parent 395O fell 
below the 60th percentile (Figure 6.10 D). In response to TRAP-6 index 
386Q fell below the 40th percentile and both parents 394Q and 395O fell 
below the 80th percentile (Figure 6.10 E). In response to U46619 index 
386Q and parent 394Q fell below the 40th percentile whereas parent 
395O fell below the 70th percentile (Figure 6.10 F). In response to 
epinephrine index 396Q fell below the 10th percentile and both parents fell 
below the 30th percentile (Figure 6.10 G). In response to ristocetin index 
386Q fell below the 10th percentile, parent 394Q fell below the 50th 




Figure 6.10 LTA aggregation responses – COX-1 mutated family + 
healthy control percentile 
 
Percentage final aggregation responses measured using LTA in response 
to arachidonic acid (A), ADP (B), collagen (C and D), TRAP-6 (E), 
U46619 (F), epinephrine (G) and ristocetin (H). Results displayed as a 
box and whisker plot with overlaid percentile indicators (dotted lines) or 
as duplicates for each patient, index 386Q (green), parent 394Q (pink)  





























































































































































































































































































































































































6.3.6 Optimul plate measured platelet aggregation – COX-1 mutated 
family + healthy controls 
 
As each family member was only tested one using this assay, it is not 
possible to statistically compare the compare the curves and so the Log 
EC50 values are displayed in a separate table (Table 6.1). However 
descriptions of the curves are as follows; in response to arachidonic acid 
index 386Q and parent 394Q had reduced aggregation responses to the 
highest four concentrations of agonist used (Figure 6.11 A). In response 
to ADP index 386Q had a reduced response to the highest concentration 
of agonist used (Figure 6.11 B). In response to collagen index 386Q and 
parent 394Q showed rightward and downward shifts in their aggregation 
curves indicating that higher concentrations of agonist were required to 
reach a lower percentage aggregation compared to control, parent 3950 
however did reach a comparable maximum aggregation to controls but 
required a much higher concentration of agonist to achieve this (Figure 
6.11 C). In response to epinephrine index 386Q had no response and 
both parents 394Q and 395O showed reduced responses to the top four 
concentrations of agonist tested (Figure 6.11 D). All three patients had 
normal responses to ristocetin (Figure 6.11 E). In response to TRAP-6 
both index 386Q and parent 395O displayed normal agonist response 
curves whereas parent 394Q showed a reduction in percentage 
aggregation for the top six concentrations of agonist used. All three 
patients had a reduced response to U46619, indicated by the rightward 
shift of each curve compared to control. Non-linear regression curves 
were fitted using GraphPad Prism software for each agonist using the 
following constraints; bottom ≥ 0 and top ≤ 100.      
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Figure 6.11 Optimul plate aggregation response curves – COX-1 
mutated family + healthy control percentile 
 
Percentage final aggregation responses measured using the Optimul 
plate assay in response to arachidonic acid (A), ADP (B), collagen (C), 
epinephrine (D), ristocetin (E) TRAP-6 (F) and U46619 (G). Results 
displayed as individual mean ± SEM for control (black, n=20), index 386Q 
(green, n=1), parent 394Q (pink, n=1) and parent 395O (blue, n=1).   

































































































































Table 6.1 Optimul data EC50 values and 95% confidence intervals 
obtained from COX-1 mutated family and healthy controls  
 
EC50 values and 95% confidence intervals for the non-linear regression 
curves fitted to the Optimul data comparing percentage aggregation of 
PRP samples obtained from the COX-1 mutated family members 










































Arachidonic	acid -3.19 -3.723 to -2.663 -4.04 -6.250 to -1.830 -4.04 -37.63 to 29.54 -3.17 -3.654 to -2.683
ADP -5.66 -5.739 to -5.572 -5.58 -5.594 to -5.569 -5.41 -5.410 to -5.405 -5.38 -5.408 to -5.360
Collagen -7.03 -7.213 to -6.854 -5.97 -6.075 to -5.867 -5.52 Not	calculated -6.22 -6.504 to -5.937
Epinephrine 0.22 -6.733 to -5.497 N/C Not	calculated N/C Not	calculated 0.50 -8.261 to -5.458
Ristocetin -2.98 -3.008 to -2.943 -2.94 Not	calculated -3.17 -3.245 to -3.095 -3.02 Not	calculated
TRAP-6 -6.08 -6.128 to -6.025 -5.23 -5.231 to -5.229 -5.83 -5.870 to -5.790 -6.12 -6.434 to -5.802
U46619 -6.93 -7.092 to -6.766 -5.61 Not	calculated -5.74 -5.766 to -5.713 -6.57 -7.087 to -6.047
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6.3.7 Measuring ATP release – COX-1 mutated family + healthy 
controls  
 
In response to arachidonic acid stimulation index 386Q and parent 395O 
showed maximum ATP releases that fell below the 10th percentile of 
healthy control responses whereas parent 394Q had an average 
response falling below the 50th percentile (Figure 6.12 A). In response to 
ADP index 386Q falls below the 30th percentile whereas both parents 
395Q and 395O fall below the 10th percentile (Figure 6.12 B). In response 
to collagen index 386Q and parent 394Q fall below the 10th percentile 
whereas on average parent 395O falls below the 60th percentile 
(Figure 6.12 C). In response to TRAP-6 agonist stimulation index 386Q 
falls below the 30th percentile, parent 394Q falls below the 40th percentile 




Figure 6.12 Agonist stimulated ATP release – COX-1 mutated family 
+ healthy controls 
 
Max ATP release (nmol) measured using a lumi aggregometer in 
response to arachidonic acid (A), ADP (B), collagen (C) and TRAP-6 (D). 
Results displayed as a box and whisker plot for each control with overlaid 
percentile indicators (dotted lines). Index case in duplicate (green), parent 













































































































































































6.3.8 Flow cytometric measurement of P-selectin expression – 
COX-1 mutated family + healthy controls  
 
Basal P-selectin expression varied between samples taken from the 
same patient on different days. If averaged samples from all three 
patients produced P-selectin mean fluorescence intensity values that fell 
above the 60th percentile and below the 80th percentile (Figure 6.13 A). In 
response to stimulation with ADP index 386Q and parent 395O fell below 
the 70th percentile whilst parent 389Q fell below the 80th percentile 
(Figure 6.13 B). In response to U46619 index 386Q fell below the 30th 
percentile whilst both parents fell below the 60th percentile 
(Figure 6.13 C). In response to ADP + U46619 386Q index fell below the 
70th whilst both parents fell below the 60th percentiles for P-selectin mean 
























Figure 6.13 Agonist stimulated surface P-selectin expression – 
COX-1 mutated family + healthy controls  
 
Mean fluorescence intensity values of platelet surface P-selectin 
expression in samples treated with vehicle (A), ADP (B), U46619 (C) or 
ADP+U46619 (D) measured using a flow cytometric assay. Results 
displayed as a box and whisker plot for control with overlaid percentile 
indicators (dotted lines) and as duplicate values for index case 386Q 


















































































































































































































































6.3.9 Comparing agonist stimulated arachidonic acid metabolite 
release from the COX-1 mutated index case compared to healthy 
controls 
 
Marked decreases in the production of thromboxane B2 (Figure 6.14 A), 
prostaglandin D2 (Figure 6.14 B), prostaglandin E2 (Figure 6.14 C), 
11-HETE (11-hydroxy-5,8,12,14-eicosatetraenoic acid) (Figure 6.14 D) 
and  15-HETE (15-hydroxy-5,8,12,14-eicosatetraenoic acid) (Figure 6.14 
F) in response to collagen (30 µg/mL) or TRAP-6 (25 µM) were detected 
between samples from the COX-1 mutated patient and controls. There 
was no difference seen in the production of 12-HETE (Figure 6.14 E) 







Figure 6.14 LC-MS/MS analysis of select arachidonic acid metabolite 
release from agonist stimulated whole blood 
 





































































































































































































































































































6.3.10 Confocal microscopy imaging of COX-1 protein expression  
 
There was no significant difference seen between COX-1 staining 
intensity between patient and control samples (Figure 6.15). The mean 
fluorescence intensity value of COX-1 staining for control platelets was 
24.71±1.30 and for patient platelets 23.99±1.53.  A t-test was used to 









Figure 6.15 Representative confocal images for COX-1 expression in 
platelets from index patient and a healthy control subject 
 
Representative images from confocal microscopy of platelet tubulin 
(green) and COX-1 (red) protein expression in platelets obtained from a 
healthy control (left panels) and from the COX-1 mutated patient (386Q) 
(right panels) using a x100 oil immersion lens alone (top panels) and a 





















6.4 Discussion  
 
In the UK rare diseases affect roughly 1 in 17 people at some point in 
their lives, and if left undiagnosed 30% of individuals with a rare disease 
will die before their fifth birthday. In an effort to tackle this The National 
Institute for Health Research (NIHR) set up the NIHR BioResource which 
aims to establish a comprehensive BioResource of participants with rare 
diseases, and their relatives, in order to identify the cause of disease and 
to improve the rate of diagnosis 229. The BRIDGE-BPD consortium feeds 
in to the NIHR BioResource and features a network of clinicians and 
researchers who are specifically working towards understanding better 
the causes of rare bleeding and platelet disorders by using next 
generation sequencing technologies in combination with tailored in-depth 
phenotyping (Figure 6.16). 
 
As part of the BRIDGE-BPD consortia I obtained patient samples in order 
to specifically test whether their bleeding disorders could be in part 
explained by abnormalities in platelet function.  In order to test multiple 
aspects of platelet function I used the following platelet assays; traditional 
light transmission aggregometry using agonist concentrations reflective of 
those used by the Genotyping and Phenotyping of Platelets (GAPP) 
study 230,231 to assess platelet aggregation, the Optimul plate assay to 
assess platelet aggregation across full concentration ranges of standard 
platelet agonists, luciferin-luciferase based luminescence aggregometry 
to assess platelet ATP release, and flow cytometric measurement of 
surface P-selectin expression to assess platelet activation. If the patient 
sample reponses appeared abnormal after these experiments further 
liquid chromatography tandem mass spectrometry to assess platelet 
arachidonic acid derived lipid content and confocal microscopy imaging to 
assess protein expression was performed.  
 
For all of these assays it was necessary to produce control data sets of 
samples from healthy volunteers to provide a reference range against 
which to compare the patient results. Owing to the fact that each patient 
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was an individual n=1 it was not possible to determine statistically the 
difference between the patient values and the control set. Consequently 
the most appropriate way to express the data was to present the control 
data set in terms of percentiles of the mean and to then assign a 
percentile value to each patient data point. This provided a means by 






Figure 6.16 Diagram outlining BRIDGE-BPD study investigations  
 
Participants are recruited into the BRIDGE-BPD study (see 
inclusion/exclusion criteria in section 6.1) for extensive phenotyping and 
DNA sequencing.     
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In total I provided in depth platelet phenotyping for 55 individuals of which 
only two families had a bleeding disorder that appeared to be of platelet 
origin according to our panel of analyses. This is not surprising as in the 
UK it is estimated that less than 15% of bleeding disorders are 
attributable to factors outside of the coagulation cascade. One case, on 
initial platelet phenotyping, presented with aspirin like LTA traces which 
were supported by reductions in response to agonists as assessed by the 
Optimul assay. These results were also seen in parent 394Q but not for 
parent 395O. When reporting these finding to the consortium we were 
made aware that the DNA sequencing, performed by the BRIDGE-BPD 
group in Cambridge, had revealed a homozygous mutation within the 
PTGS1 gene in the index case and in parent 394Q. Parent 395O was 
heterozygous for the same mutation.   
 
The PTGS1 gene encodes for the prostaglandin G/H synthase-1 also 
known as cyclooxygenase-1 (COX-1) enzyme. Once liberated from 
membrane phospholipids by phospholipase enzymes (see chapter 5), 
free arachidonic acid becomes the substrate for the COX enzymes of 
which there are two isoforms; COX-1 and COX-2 176. This current 
investigation is only concerned with the platelet specific action of the 
COX-1 enzyme. COX-1 is a constitutively expressed enzyme that 
produces prostanoids mainly involved in normal homeostasis. Through 
two catalytic steps (Figure 6.1) the enzyme converts arachidonic acid into 
biologically active prostanoids 177,232. In the platelet these include TXA2 
functioning to promote platelet aggregation, PGE2 functioning to promote 
platelet aggregation at low concentration and to inhibit platelet 
aggregation at high concentrations and PGD2 functioning to inhibit platelet 
aggregation.   
 
The PTGS1 mutation identified in the index case and parent 394Q was a 
homozygous missense mutation G>C found on chromosome 9 resulting 
in a tryptophan to serine amino acid change within exon 8. The in-depth 
platelet function testing I carried out on these patient samples revealed 
multiple deviations from normal platelet function that appeared in part 
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similar to results produced by pharmacological inhibition of the COX-1 
enzyme by aspirin 233–237.  
 
Light transmission aggregometry results revealed percentage 
aggregation values that fell below the 10th percentile of the normal range 
in response to stimulation with arachidonic acid, collagen and epinephrine 
(Figure 6.10) consistent with the loss of thromboxane A2 release from the 
platelet due to COX-1 inhibition. Thromboxane A2 release is essential to 
sustain and amplify platelet-activating responses following stimulation by 
other agonists 206,238.  
 
These results were supported by the Optimul assay with curves showing 
downwards and/or rightwards shifts for percentage aggregation recorded 
in response to arachidonic acid, collagen, epinephrine, TRAP-6 and 
U46619 (Figure 6.11).  In addition, there were marked reductions in 
aggregation in response to ADP in both assays suggesting that this 
patient may have another form of platelet dysfunction acting in 
combination with the confirmed aspirin-like defect. 
 
Further support also came from measurements of ATP release, used as 
an indicator of platelet activation, where the responses of platelets from 
the index patient were below the 20th percentile of the control range for 
each agonist (Figure 6.12). Lipid release profiles indicate a reduction in 
all five major platelet COX-1 products measured supportive of a COX-1 
inhibition as documented my by group previously. Levels of 12-HETE 
remained unchanged between the patient and control groups as this 
eicosanoid is not a platelet COX-1 product (Figure 6.14) 239. In order to 
test statistically the significance of these results more patient samples 
need to be tested.   
 
The mutation had no observable effect on COX-1 protein expression as 
determined by confocal microscopy (Figure 6.15) indicating that the 
changes to platelet function observed cannot be attributed to decreased 
protein levels. However this data is in opposition to western blot analyses 
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carried by BRIDGE-BPD consortium partners in Leuven who show almost 
total absence of the COX-1 protein. Replicates are needed for both 
assays in order to definitively determine the effects the mutation has on 
COX-1 protein expression. Furthermore qRT-PCR quantification of 
COX-1 mRNA expression needs to be carried out in order to assess the 
impact the mutation may be having at an mRNA level. In addition it would 
be interesting to collect urine samples from each family member and to 
use an ELISA kit to look for various eicosanoid metabolites such as the 
thromboxane B2 – the stable metabolite of thromboxane A2 cleared in 
urine. Such kits are commercially available, easy to use and would help 
to clarify the contradicting protein expression data. Alternatively 
LC-MS/MS could be used on the urine samples to identify all potential 
eicosanoid metabolites present in the sample 240.  
 
Interestingly the index case also fell below the 10th percentile for 
percentage aggregation in response to ristocetin on the LTA assay 
(Figure 6.10 H) and the Optimul curve for ristocetin displayed a 
downward shift (Figure 6.11 E). This could indicate that as well as having 
an aspirin-like defect the index patient might also have a mild form of von 
Willebrand’s disease (vWD). vWD usually results from a deficiency and/or 
abnormality of von Willebrand Factor (vWF) and is the most frequently 
diagnosed bleeding disorder 241–243. The main role of vWF is to promote 
the adhesion of platelets to the subendothelium via the platelet 
glycoprotein Ib receptor and to facilitate platelet-platelet interactions via 
the platelet glycoprotein IIb/IIIa receptor. These events lead to the 
formation of a stable platelet plug functioning to stop bleeding at the site 
of injury 244,245. Absent or defective vWF would therefore produce 
bleeding symptoms. Reduced measures of ristocetin induced platelet 
agglutination are used clinically to diagnose vWD and to distinguish from 
other defects of platelet aggregation 242,246. The idea that the index 
patient may have a mild form of vWD in addition to the COX-1 mutation is 
supported by her history of bleeding symptoms (haemoptysis, epistaxis, 
peri-operative bleeding and a tendency to bruise easily) that would not be 
accounted for by an aspirin-like defect in isolation. Within the platelet 
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research community there is growing support for the idea that in order to 
produce the clinical symptoms of a bleeding disorder there must be 
simultaneous defects affecting both the platelets and the coagulation 
system. This ‘double hit’ theory implies that a COX-1 mutation alone 
would be insufficient to cause this particular patient phenotype. Further 
investigations focussing on the coagulation system need to be 
undertaken for this patient.   
 
In conclusion, in depth platelet function testing tailored to individual cases 
with comparisons to robust control data sets are essential for the 
diagnosis of platelet bleeding disorders and for guiding DNA/RNA 
sequencing investigations for the identification of causal mutations. Using 
this approach I phenotyped 55 individuals who reported bleeding 
symptoms with unknown molecular aetiology. Following on from this I 
focussed particularly upon one family who had a confirmed mutation to 
the PTGS1 gene encoding for the COX-1 enzyme and found significant 
impairments in platelet function closely resembling an aspirin-like defect 
for the index case which were also reflected in the parent 394Q data. In 
addition to this the index case also has indications of a mild vWD that 
could also be contributing to her bleeding tendency. This chapter clearly 
shows the benefit of combining deep phenotyping with next generation 


















Platelets play an active part in a diverse range of biological processes 
and are associated with multiple disease states 247. The striking 
observations that less than one 20th of the total platelet population is 
required to prevent bleeding 248, that platelet granules contain a diverse 
range of mediators 249 and that platelet surface receptors exist with no 
obvious link to haemostasis have led many researchers to investigate 
platelet functions beyond haemostasis 250,251. As such more attention is 
being given to the role of less appreciated features of platelet biology, 
such as platelet RNA species, in an attempt to better define mechanisms 
determining platelet function. Consequentially, and with the advent of 
powerful next generation sequencing technologies, both human and 
mouse platelet transcriptomes data sets were published in their entirety 
and made publically available resources back in 2011 54. Since then there 
have been multiple studies providing evidence to support the idea that 
platelet mRNA expression profiles are altered in human disease 77,252,253. 
In light of these studies, further investigations focussing on platelet mRNA 
have the potential to provide new sights into platelet function and so aid 
the discovery of novel biomarkers of disease.  
 
The importance and clinical utility of studying platelet RNA has been 
made evident with the launch of Illumina’s new daughter company GRAIL 
254.  GRAIL is a life science company that aims to detect cancer before a 
patient is symptomatic through deep sequencing of circulating tumour 
DNA/RNA found within blood plasma 255. With financial backing from the 
likes of Bill Gates and Jeff Bezos and with clinical trails underway there is 
a lot of excitement surrounding Illumina’s new venture. It is relevant to 
highlight that prior to the development of GRAIL the research group of 
Thomas Wurdinger at VU University in Amsterdam had published 
extensively on the ability of platelets to take up RNA species from other 
cell types and subsequently then on the use of platelet RNA signatures 
for the detection of cancer 88,256,257. In turn Thomas Wurdinger formed a 
company called ThromboDX which was later purchased by Illumina for 
€70 million in 2017 with the aim of integrating the company’s 
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platelet-powered technology into the deep sequencing platforms being 
developed at GRAIL. 
 
The study of platelet RNA relies fundamentally on the ability to isolate 
platelets from whole blood. For platelet RNA analysis it is essential that 
contamination of samples by other nucleated cell types with very much 
larger quantities of RNA, such as white blood cells, is kept to a minimum. 
It is also important that the isolation technique causes minimal activation 
to avoid, for instance, losing certain sub-populations in the process. 
Platelet researchers have described many methods for blood collection 
and platelet isolation but there is no consensus as to which is best. This 
wide variation in techniques is probably the major reason why there is so 
much variability in reports of platelet function testing between different 
laboratories 258,259. Thus, comparing the variable aspects of the blood 
collection methods, in this case anticoagulant selection and choice of 
blood taking receptacle, was a logic beginning to this thesis. In addition, it 
was also essential to identify the optimal technique for obtaining a pure 
platelet population before proceeding onto any experiments requiring the 
isolation of platelet RNAs and the platelet sub-populations rich in them. 
Through systematic comparisons using LTA and Optimul plate assays as 
indicators of platelet function I found that there was no significant 
difference between any of the anticoagulants or blood receptacles used. 
Selection of a blood taking method should therefore be guided by the 
specific assay endpoint, for example sodium citrate may alter in vitro 
platelet reactivity as it is a calcium chelator, as well as by the 
phlebotomist’s personal preference. Following on from this I showed that 
simple single step centrifugation of whole blood to obtain PRP produces a 
large reduction in contaminating white blood cell number and RNA 
content as measured using flow cytometry and qRT-PCR. This reduction 
equates to roughly a 500-fold decrease that is only further enriched 
around 11-fold through the use of additional syringe filtering or MACS 
sorting techniques. This extra enrichment is negated by the potential for 
platelet activation caused by these more involved protocols. Importantly 
the simple production of PRP requires much less labour and expense 
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than more involved techniques making it a suitable method for use in 
larger population based studies or when testing multiple family members.  
 
The optimisation of a protocol for platelet isolation then allowed me to 
investigate a platelet sub-population assumed to be both rich in RNA and 
to be more reactive 260. These so called newly formed reticulated platelets 
can be identified from the general platelet population using the nucleic 
acid binding dye thiazole orange with the idea being that reticulated 
platelets will stain brighter for thiazole orange than other platelet 
sub-populations because they contain greater amounts of RNA 104. The 
non-specific nature of thiazole orange however means that all RNA 
species, not just mRNA, and free nucleotides in platelet granules will all 
be stained. This factor has led to some disagreement within the field 
prompting investigators to question whether thiazole orange based 
analyses may be skewed by the potential for larger and more granular 
platelets to take up more dye 261. This concern can in part be overcome 
by stimulating platelets to release their granule content, but this technique 
is not suitable if one wants to preserve platelet function for testing in other 
assays. In order to address these concerns, I conducted qRT-PCR 
experiments on flow cytometric cell sorted reticulated, intermediate and 
non-reticulated platelet subpopulations and showed definitively for the 
first time that reticulated platelets express significantly more platelet 
specific mRNA than their non-reticulated counterparts. In addition, other 
preliminary studies from our group, not documented in this thesis, 
indicate that there is no significant difference in size between platelets 
present in reticulated and non-reticulated sub-populations. The 
production of newer dyes with the ability to bind mRNA species 
exclusively, perhaps by targeting the poly-A tail, or those that possess the 
ability to only fluoresce when a certain concentration of RNA is bound 
would be of great utility to the field.   
 
Establishing a protocol that isolated reticulated platelets whilst preserving 
their function allowed me then to investigate the reactive potential of this 
subpopulation in attempt to elucidate some of the mechanisms which 
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may underpin the link between increased reticulated platelet counts and 
the occurrence of acute coronary syndrome. Using various platelet 
function assays modified to work for low concentrations of cell sorted 
platelets I demonstrate that the reticulated platelet sub-population 
express higher amounts of surface CD62P and release larger 
concentrations of ATP in response to agonist stimulation. Additionally, my 
data indicates that this sub-population shows elevated reactivity during 
aggregate formation shown through the disproportional recruitment of 
reticulated platelets into the centre of forming aggregates; a phenomenon 
that I observed in both cell-sorted samples and in PRP. Despite 
comprising only 10% of the total platelet count the increased reactivity of 
reticulated platelets demonstrated in these investigations provide 
evidence that this sub-population may be a driver of the thrombotic 
response.  
 
This data supports clinical observations linking increased reticulated 
platelet counts, not only to the incidence of acute coronary syndrome 
262,263, but also to the increased risk of cardiovascular disease in patient 
populations, such as those with diabetes and chronic kidney disease 
100,264,265, whom are known to have increased platelet turnovers and 
consequentially a greater proportion of reticulated platelets. 
Understanding the reactive potential of reticulated platelets is also 
pertinent to the study of antiplatelet therapy regimens especially in patient 
groups that display high on treatment platelet reactivity. In a paper from 
our group this year we showed, using samples from patients receiving the 
most commonly prescribed antiplatelet regimen of aspirin plus the P2Y12 
inhibitor clopidogrel, that reticulated platelets act as seeds for the 
formation of aggregates even in the presence of antiplatelet therapies 98. 
This observation was directly linked to the emergence of newly formed 
reticulated platelet sub-population that was not previously exposed to the 
pharmacological inhibitors owing to the drugs’ short pharmacokinetic 
half-lives. Strikingly this phenomenon was not seen in patients receiving 
aspirin plus the newer P2Y12 inhibitor ticagrelor which is a circulating 
inhibitor 266. This study provides a mechanism by which reticulated 
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platelets may reduce the efficacy of permanently acting but 
pharmacokinetically short-lasting antiplatelet therapies, notably aspirin 
plus clopidogrel. The ability of drugs to target reticulated platelets is 
clearly an important consideration for future antiplatelet therapies and at 
the level of personalised therapy could be tracked by assays particularly 
designed to distinguish newly formed reticulated platelets from older 
non-reticulated platelets. Identifying characteristics more tractable to 
assay development than RNA content would be a very good way to begin 
this new phase of anti-platelet prophylaxis.  
 
An interesting future investigation to understand better the mRNA content 
of reticulated platelets would be to run RNA-Seq experiments comparing 
transcript expression profiles between reticulated and non-reticulated 
platelets. This would help to answer the question as to whether 
reticulated platelets contain more RNA in general or whether they are 
enriched in specific genes and whether or not those genes are important 
to pathways involved in platelet activation. The low RNA concentration 
within individual platelets, it is postulated that older platelets may contain 
no RNA at all, combined with lengthy cell sorting process limits the 
application of RNA-Seq for these platelet sub-populations. In the future, 
improvements in single-cell sequencing technologies that permit 
sequencing of small cells with low amounts of starting material could 
solve this problem.    
  
Studies of the reticulated versus non-reticulated platelet proteomes using 
techniques such as LC-MS/MS would also be beneficial and could help to 
determine whether an increase in mRNA content equates to increases in 
protein expression. In addition, the use of newer non-radioactive assays, 
such as the Click-iT AHA L-azidohomoalanine kit from ThermoFisher, for 
the evaluation of protein synthesis in vitro could be used to assess the 
ability of reticulated platelets to translate mRNA into protein. 
Unfortunately for platelet researchers, a lot of starting material is needed 
for these types of analyses and these assays require amounts of platelets 
that would take a considerable time to sort and separate.  
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Another interesting continuation of the reticulated platelet work would be 
to use animal models of thrombosis in combination with in vivo labelling 
of the reticulated and non-reticulated platelet subpopulations. A 
mechanical/chemical injury promoting thrombus formation could then be 
applied upon a vessel wall and the resulting thrombus extracted. 
Microscopy could then be used to ascertain the relative contributions of 
both reticulated and non-reticulated platelets to the formation of the 
thrombus. If our in vitro experiments are correct, one would expect to see 
a greater number of reticulated platelets present in the thrombus and for 
those reticulated platelets to be forming aggregate cores. Indeed these 
investigations would compliment work previously published by platelet 
research groups in Swansea 267–269, Sydney 270,271 and Maastricht 272–275 
who have been combining traditional platelet function assays with 
advanced rheological analyses to understand better the role of platelets 
in thrombus formation and composition. Together these groups have 
provided evidence to suggest that thrombus formation occurs in distinct 
but complimentary stages involving biomechanical processes followed by 
soluble-agonist dependent mechanisms. They also emphasise the idea 
that a thrombus contains different subpopulations of platelets that play 
distinct roles in the processes leading up the formation of a stable blood 
clot. My in vitro imagestream data contributes to this growing body of 
evidence showing that aggregates are composed of a heterogeneous mix 
of platelets whilst helping to further the discussion by suggesting that 
thrombi may be composed of multiple layers of platelets each with distinct 
functional capabilities and/or different responsiveness to antiplatelet 
therapies. 
 
I also would like to have conducted in-depth imaging studies comparing 
the two subpopulations in order to help identify some of the physical 
characteristics that may support the differences in reactivity observed. 
For example, quantification of granule number, content and size as well 
as quantification of mitochondrial number would have been informative.  
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A platelets ability to adhere to an injured vessel wall is another essential 
feature of platelet function, as such assays using fluorescently labelled 
platelets in whole blood which is then pumped through a microfluidics 
chamber coated with adhesive proteins such as collagen and fibrinogen 
can be used to assess the adhesive properties of different platelet 
samples 276–279. Although I made many attempts at optimising protocols 
for comparing the adhesive properties of the reticulated platelet 
subpopulations I was unable to get the sorted platelets to stick to the 
adherent surface. More work is needed to develop this method further as 
it could be used to give more precise detail as to how the different 
subpopulations behave in the formation of more physiologically relevant 
aggregates in whole blood. 
 
Following on from the characterisation of RNA rich subpopulations and 
the optimisation of protocols for platelet isolation and RNA extraction I 
sought to investigate the relationships between genomic DNA, platelet 
specific mRNA and platelet function. I was able to achieve this by 
obtaining blood samples from a patient known to have a homozygous 
mutation in the PLA2G4A gene causing inactivation of cPLA2α enzymatic 
activity and using these to carry out both platelet function and RNA-Seq 
investigations. Using LTA and Optimul plate assay I demonstrate 
significant reductions in percentage aggregation recorded in response to 
the platelet agonists ADP, collagen, epinephrine and U46619 as well as 
reduced ATP release in response to collagen in platelet samples from this 
patient.  These results can be explained by the loss of arachidonic acid 
derived eicosanoid production, in particular thromboxane A2, due to 
non-existent cPLA2α enzymatic function. It is interesting to note that this 
patient reports no associated symptoms of bleeding despite having a 
clear platelet dysfunction; this is in contrast to the PTGS1 mutated patient 
I also reported on who had an extensive history of bleeding symptoms in 
spite of having a similar platelet phenotype to the PLA2G4A case. This 
further supports my supposition that the PTGS1 case has an additional 
mutation, perhaps affecting an aspect of the coagulation cascade, to thus 
account for her clinical presentation.  
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Owing to the fact that platelets from the PLA2G4A mutated patient were 
unable to produce eicosanoids central to platelet function I hypothesised 
that there may be differences in the selective sorting of mRNAs into 
platelets by megakaryocytes and so a change in the platelet 
transcriptome. I anticipated there being a decrease in mRNA transcripts 
that encode for proteins playing essential roles in eicosanoid driven 
pathways of platelet activation. To assess this, I defined the platelet 
transcriptomes of both healthy control platelet samples and PLA2G4A 
mutated patient platelet samples using RNA-Seq and compared the 
expression of transcripts detected using differential expression analysis. 
My results correlated well with other published RNA-Seq experiments. As 
more studies are conducted data can be pooled to create a more robust 
data set representative of the ‘healthy’ platelet transcriptome from which 
to make comparisons to.  Although I found no significant difference in the 
levels of expression for any transcripts explicitly linked to eicosanoid 
activity I did find twenty-six other transcripts that were significantly up 
regulated in the patient samples compared to controls. Of these 
twenty-six, four (S100A8, S100A9, S100A12 and SLP1) had previously 
been reported to be associated with aspects of platelet function and/or 
cardiovascular disease making them interesting candidates for the 
establishment of novel biomarkers for disease. Future experiments 
should seek to ascertain whether these up-regulated transcripts translate 
into increased protein expression. Increasing the sample size in both the 
control and patient groups would strengthen the analyses however there 
is some debate as to whether taking multiple samples from the same 
patients does in reality just equate to a n=1 group size. The use of 
RNA-Seq in combination with platelet function testing enabled me to 
assess the impact of genomic mutations on both platelet mRNA content 
and platelet reactivity, giving a more complete view of the platelet specific 
consequences caused by loss of cPLA2α activity.  
 
As well as being an informative basic science tool, next generation 
sequencing techniques can play a major role in the clinic. Indeed, earlier 
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this year in her annual report entitled ‘Generation Genome’, England’s 
chief medical officer, Dame Sally Davies, called for NHS services to 
routinely perform whole genome sequencing on patient blood samples 
and biopsies. Resources are currently focussed on patients with cancer 
but will be shared to other areas of medicine once centralised genomic 
services are established. The report stresses particularly the urgent need 
for whole genome sequencing for patients with infectious or rare diseases 
280,281.  
 
This news bodes well for studies, such BRIDGE-BPD, which have been 
designed specially to meet the unmet diagnostic needs of those living 
with rare bleeding disorders. By providing patients with diagnoses for 
such rare bleeding disorders clinicians will be better equipped to monitor, 
manage or treat the patients’ symptoms whilst basic scientists will gain 
novel insights into molecular pathways underling haemostasis, 
thrombosis and bleeding. The clinical success of such studies relies 
critically on the ability to combine the sequencing data with in-depth 
sample phenotyping 282–285. As such within this thesis I developed a 
protocol for the phenotyping of platelets from patients with unknown 
bleeding disorders. This protocol involved multiple platelet function 
assays which could be scaled according to how many patient samples 
were collected per day. Importantly I selected assays that could 
interrogate different aspects of platelet function and that could be 
modified in response to any clinically relevant information received. Using 
this individualised approach, I was able to provide in depth platelet 
phenotyping data that could be paired with the DNA sequencing data to 
highlight the functional consequences of any mutations found. I 
demonstrate this process by presenting a case study of a family with a 
mutation within the PTGS1 gene encoding for the COX-1 enzyme - a 
protein known to play an essential role in platelet reactivity. My initial 
phenotyping results using the LTA and Optimul assays revealed a clear 
aspirin like defect defined by reduced responses to the platelet agonists 
arachidonic acid, collagen and epinephrine for both the index case and 
parent 394Q but not for parent 395O. Further investigations revealed 
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reductions in markers of platelet activation including P-selectin 
expression and ATP release. Eicosanoid production in response to 
agonist stimulation was also diminished for the index patient. These 
findings are consistent with the loss of COX-1 function. DNA sequencing 
results validated these phenotypic findings, showing that the index case 
and parent 394Q were both homozygous for the specific PTGS1 
mutation. This may also suggest that this mutation may be more 
prevalent in the Iranian population. To investigate these possibilities the 
index cases’ extended family will also be recruited into the BRIDGE-BPD 
study for DNA sequencing and platelet function testing.  
 
In addition to the aspirin-like defect I also found reduced aggregation 
responses to ristocetin indicative of a vWD like defect in the index case. 
In order to confirm this quantification of vWF levels in the blood using a 
von Willebrand factor antigen test should be carried out. It will also be 
important to go back through the DNA sequencing data and to look for 
any additional mutations that may be occurring within genes known to be 
associated to vWD. The idea of needing two separate mutations 
occurring in different genes to produce a clinical bleeding disorder is not a 
new theory 286 however rigorous supportive in vivo evidence is lacking. 
The severity of the patients bleeding symptoms also lends support to the 
idea that a platelet disorder alone would not be enough to cause their 
particular bleeding defect. Further support for this hypothesis is given by 
the lack of bleeding phenotype reported for parent 394Q despite them 
having a clinical aspirin-like phenotype and the same homozygotic 
mutation. This particular case study clearly illustrates the benefit of 
combining deep phenotyping with next generation sequencing to 
understand the causation of bleeding disorders and to provide molecular 
diagnoses for patients living with unknown bleeding and platelet 
disorders.    
 
Together the investigations carried out within this thesis highlight the 
importance of understanding genomic influences that have the potential 
to impact upon platelet function and to thus provide fresh insights into the 
 218 
molecular pathways determining platelet reactivity. This thesis provides 
the tools for conducting such experiments by establishing robust 
protocols for the isolation of RNA rich platelet sub-populations and for the 
extraction of mRNA species. Using such protocols will ensure that all 
platelet sub-populations are represented in downstream investigations of 
the platelet transcriptome. This thesis also demonstrates the ability of 
genomic DNA mutations to alter the platelet transcriptome, demonstrated 
using the PLA2G4A case study, and to have significant effects upon 
platelet function. The clinical usefulness of such observations will only 
become evident by combining genomic data with in-depth, clinically 
tailored, ex vivo platelet phenotyping as highlighted by the PTGS1 case 
study. This puts us a step further along the path of personalised medicine 
both for patients with bleeding disorders and for patients requiring safe 
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